Always follow your funding opportunity's instructions for application format. Although this 

application demonstrates good grantsmanship, time has passed since the grantee applied. The 

sample may not reflect the latest format or rules. NIAID posts new samples periodically: 

https://www.niaid.nih.gov/grants-contracts/sample-applications

The text of the application is copyrighted. You may use it only for nonprofit educational 

purposes provided the document remains unchanged and the PI, the grantee organization, 

and NIAID are credited.

Note on Section 508 conformance and accessibility: We have reformatted these samples to 

improve accessibility for people with disabilities and users of assistive technology. If you have 

trouble accessing the content, please contact the NIAID Office of Knowledge and Educational 

Resources

at deaweb@niaid.nih.gov.

PI: Tran, Tuan Manh Title: Defining clinical and sterile immunity to Plasmodium falciparum infection using 

systems biology approaches

Received: 07/12/2016 FOA: PA16-191 Council: 01/2017

Competition ID: FORMS-D FOA Title: MENTORED CLINICAL SCIENTIST RESEARCH CAREER 

DEVELOPMENT AWARD (PARENT K08)

1 K08 AI125682-01A1 Dual: Accession Number: 3956054

IPF: 577806 Organization: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS

Former Number: Department:

IRG/SRG: MID-B AIDS: N Expedited: N

Subtotal Direct Costs 

(excludes consortium F&A) 

Year 1:

Year 2:

Year 3:

Year 4:

Year 5:

Animals: N 

Humans: N 

Clinical Trial: N

Current HS Code: E4 

HESC: N

New Investigator: N

Early Stage Investigator: N

Senior/Key Personnel: Organization: Role Category:

Tuan Tran INDIANA UNIVERSITY PD/PI

Chandy John Indiana University Other (Specify)-Mentor

Wanzhu Tu Ph.D Indiana University Other (Specify)-Co-Mentor

Peter Crompton National Institute of Allergy and 

Infectious Diseases

Other (Specify)-Co-mentor

Lang Li Indiana University Other (Specify)-Co-mentor

Sangeeta Bhatia Massachusetts Institute of Technology Other (Specify)-Collaborator

Philip Felgner University of California Other (Specify)-Collaborator

Scott Michaels Indiana University Other (Specify)-Collaborator

Kara Wools-Kaloustian Indiana University Other (Specify)-Collaborator
OMB Number: 4040-0001

Expiration Date: 06/30/2016

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date:

2016-07-12T10:54:42.000-04:00

APPLICATION FOR FEDERAL ASSISTANCE

SF 424 (R&R)

3. DATE RECEIVED BY STATE State Application Identifier

1. TYPE OF SUBMISSION* 4.a. Federal Identifier

❍ Pre-application ● Application ❍ Changed/Corrected

Application

b. Agency Routing Number

2. DATE SUBMITTED Application Identifier c. Previous Grants.gov Tracking Number

5. APPLICANT INFORMATION Organizational DUNS*: 

Legal Name*: The Trustees of Indiana University

Department:

Division:

Street1*:

Street2:

City*:

County:

State*:

Province:

Country*:

ZIP / Postal Code*:

Person to be contacted on matters involving this application

Prefix: Mr. First Name*: Jim Middle Name: Last Name*: Becker Suffix: 

Position/Title: Executive Director, Grant Administration

Street1*: Office of Research Administration

Street2:

City*:

County:

State*:

Province:

Country*:

ZIP / Postal Code*:

Phone Number*: Fax Number: Email: 

6. EMPLOYER IDENTIFICATION NUMBER (EIN) or (TIN)*

7. TYPE OF APPLICANT* H: Public/State Controlled Institution of Higher Education

Other (Specify):

Small Business Organization Type ❍ Women Owned ❍ Socially and Economically Disadvantaged

8. TYPE OF APPLICATION* If Revision, mark appropriate box(es).

❍ New ● Resubmission ❍ A. Increase Award ❍ B. Decrease Award ❍ C. Increase Duration

❍ Renewal ❍ Continuation ❍ Revision ❍ D. Decrease Duration ❍ E. Other (specify) :

Is this application being submitted to other agencies?* ❍Yes ●No What other Agencies?

9. NAME OF FEDERAL AGENCY*

National Institutes of Health

10. CATALOG OF FEDERAL DOMESTIC ASSISTANCE NUMBER

TITLE:

11. DESCRIPTIVE TITLE OF APPLICANT'S PROJECT*

Defining clinical and sterile immunity to Plasmodium falciparum infection using systems biology approaches

12. PROPOSED PROJECT

Start Date* Ending Date*

04/01/2017 03/31/2022

13. CONGRESSIONAL DISTRICTS OF APPLICANT

IN-007
Contact PD/PI: Tran, Tuan Manh

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date:

2016-07-12T10:54:42.000-04:00

SF 424 (R&R) APPLICATION FOR FEDERAL ASSISTANCE Page 2

14. PROJECT DIRECTOR/PRINCIPAL INVESTIGATOR CONTACT INFORMATION

Prefix: Dr. First Name*: Tuan Middle Name: Manh Last Name*: Tran Suffix: 

Position/Title: Assistant Professor of Medicine

Organization Name*: INDIANA UNIVERSITY

Department:

Division:

Street1*:

Street2:

City*:

County:

State*:

Province:

Country*:

ZIP / Postal Code*:

Phone Number*: Fax Number: Email*:

15. ESTIMATED PROJECT FUNDING

a. Total Federal Funds Requested* $

b. Total Non-Federal Funds* $0.00

c. Total Federal & Non-Federal Funds* $

d. Estimated Program Income* $0.00

16. IS APPLICATION SUBJECT TO REVIEW BY STATE

EXECUTIVE ORDER 12372 PROCESS?*

a. YES ❍ THIS PREAPPLICATION/APPLICATION WAS MADE

AVAILABLE TO THE STATE EXECUTIVE ORDER 12372

PROCESS FOR REVIEW ON:

DATE:

b. NO ● PROGRAM IS NOT COVERED BY E.O. 12372; OR

❍ PROGRAM HAS NOT BEEN SELECTED BY STATE FOR

REVIEW

17. By signing this application, I certify (1) to the statements contained in the list of certifications* and (2) that the statements herein

are true, complete and accurate to the best of my knowledge. I also provide the required assurances * and agree to comply with

any resulting terms if I accept an award. I am aware that any false, fictitious, or fraudulent statements or claims may subject me to

criminal, civil, or administrative penalties. (U.S. Code, Title 18, Section 1001)

● I agree*

* The list of certifications and assurances, or an Internet site where you may obtain this list, is contained in the announcement or agency specific instructions.

18. SFLLL or OTHER EXPLANATORY DOCUMENTATION File Name: 

19. AUTHORIZED REPRESENTATIVE

Prefix: Mr. First Name*: John Middle Name: W. Last Name*: Talbott Suffix: 

Position/Title*: Assistant Vice President for Research Admin.

Organization Name*: The Trustees of Indiana University

Department: Office of Research Aministrati

Division:

Street1*:

Street2:

City*:

County:

State*:

Province:

Country*:

ZIP / Postal Code*:

Phone Number*: Fax Number: Email*: 

Signature of Authorized Representative*

John Talbott

Date Signed*

07/12/2016

20. PRE-APPLICATION File Name: Mime Type:

21. COVER LETTER ATTACHMENT File Name:K08_Cover_Letter_07012016.pdf Mime Type: application/pdf
424 R&R and PHS-398 Specific

Table Of Contents Page Numbers

SF 424 R&R Cover Page----------------------------------------------------------------------------------------- 1

 Table of Contents------------------------------------------------------------------------- 3

Performance Sites--------------------------------------------------------------------------------------------- 4

Research & Related Other Project Information------------------------------------------------------------------ 5

 Project Summary/Abstract(Description)----------------------------------------------------- 6

 Project Narrative------------------------------------------------------------------------- 7

 Bibliography & References Cited----------------------------------------------------------- 8

 Facilities & Other Resources-------------------------------------------------------------- 14

 Equipment--------------------------------------------------------------------------------- 17

Research & Related Senior/Key Person-------------------------------------------------------------------------- 18

Research & Related Budget Year - 1---------------------------------------------------------------------------- 64

Research & Related Budget Year - 2---------------------------------------------------------------------------- 67

Research & Related Budget Year - 3---------------------------------------------------------------------------- 70

Research & Related Budget Year - 4---------------------------------------------------------------------------- 73

Research & Related Budget Year - 5---------------------------------------------------------------------------- 76

Budget Justification------------------------------------------------------------------------------------------ 79

Research & Related Cumulative Budget-------------------------------------------------------------------------- 80

PHS398 Cover Page Supplement---------------------------------------------------------------------------------- 81

PHS 398 Career Development Award------------------------------------------------------------------------------ 83

 Introduction to Application--------------------------------------------------------------- 85

 Candidate Information and Goals for Career Development------------------------------------ 86

 Specific Aims----------------------------------------------------------------------------- 89

 Research Strategy------------------------------------------------------------------------- 90

 Training in the Responsible Conduct of Research------------------------------------------- 99

 Plans and Statements of Mentor and Co-Mentor(s)------------------------------------------- 100

 Letters of Support from Collaborators,Contributors, and Consultants----------------------- 106

 Description of Institutional Environment-------------------------------------------------- 110

 Institutional Commitment to Candidate's Research Career Development----------------------- 111

 Protection of Human Subjects-------------------------------------------------------------- 112

 Inclusion of Women and Minorities--------------------------------------------------------- 114

 PHS Inclusion Enrollment Report----------------------------------------------------------- 115

 Inclusion of Children--------------------------------------------------------------------- 116

 Resource Sharing-------------------------------------------------------------------------- 117

 Authentication of Key Biological and/or Chemical Resources-------------------------------- 118

Contact PD/PI: Tran, Tuan Manh

Table of Contents Page 3
Contact PD/PI: Tran, Tuan Manh

OMB Number: 4040-0010

Expiration Date: 06/30/2016

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191. Received Date:

2016-07-12T10:54:42.000-04:00

Project/Performance Site Location(s)

Project/Performance Site Primary Location ❍ I am submitting an application as an individual, and not on behalf of

a company, state, local or tribal government, academia, or other type of

organization.

Organization Name: The Trustees of Indiana University

Duns Number:

Street1*:

Street2:

City*:

County:

State*:

Province:

Country*:

Zip / Postal Code*:

Project/Performance Site Congressional District*: IN-007

File Name Mime Type

Additional Location(s)

 Page 4
Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191. Received Date:

2016-07-12T10:54:42.000-04:00

OMB Number: 4040-0001

Expiration Date: 06/30/2016

RESEARCH & RELATED Other Project Information

1. Are Human Subjects Involved?* ● Yes ❍ No

1.a. If YES to Human Subjects

Is the Project Exempt from Federal regulations? ● Yes ❍ No

If YES, check appropriate exemption number: 1 2 3 ✔ 4 5 6

If NO, is the IRB review Pending? ❍ Yes ❍ No

IRB Approval Date:

Human Subject Assurance Number 00003544

2. Are Vertebrate Animals Used?* ❍ Yes ● No

2.a. If YES to Vertebrate Animals

Is the IACUC review Pending? ❍ Yes ❍ No

IACUC Approval Date:

Animal Welfare Assurance Number

3. Is proprietary/privileged information included in the application?* ❍ Yes ● No

4.a. Does this project have an actual or potential impact - positive or negative - on the environment?* ❍ Yes ● No

4.b. If yes, please explain:

4.c. If this project has an actual or potential impact on the environment, has an exemption been authorized or an

environmental assessment (EA) or environmental impact statement (EIS) been performed?

❍ Yes ❍ No

4.d. If yes, please explain:

5. Is the research performance site designated, or eligible to be designated, as a historic place?* ❍ Yes ● No

5.a. If yes, please explain:

6. Does this project involve activities outside the United States or partnership with international

collaborators?*

❍ Yes ● No

6.a. If yes, identify countries:

6.b. Optional Explanation:

Filename

7. Project Summary/Abstract* K08_Project_SummaryAbstract_07082016.pdfMime Type: application/pdf

8. Project Narrative* K08_A1__07012016__Project_Narrative.pdf Mime Type: application/pdf

9. Bibliography & References Cited K08_References_Cited_07062016.pdf Mime Type: application/pdf

10.Facilities & Other Resources K08__Facilities_and_Resources__07082016.pdf Mime Type: application/pdf

11.Equipment K08_Equipment_07082016.pdf Mime Type: application/pdf

Contact PD/PI: Tran, Tuan Manh

 Page 5
Project Summary/Abstract

Malaria afflicts ~198 million people yearly, with 438,000 malaria deaths due to Plasmodium falciparum, 

underscoring the need for a highly effective malaria vaccine. The first licensed malaria vaccine, RTS,S, may 

provide much-needed reductions in morbidity and mortality, but its modest efficacy in reducing clinical malaria 

in the target population of African infants leaves ample margin for improvement. A better understanding of 

immunity to P. falciparum in naturally exposed populations can inform efforts to improve malaria vaccine 

design. To date, there are no reliable correlates of protection from either symptomatic P. falciparum infection 

(clinical immunity) or parasitemia (sterile immunity). Systems biology utilizes computational modeling of largescale data sets to elucidate complex biological networks and has the potential to reveal novel predictors and 

mechanisms of malaria protection when applied to well-designed clinical cohort studies. 

 

In this project, the candidate proposes to assess immune predictors of natural protection from P. falciparum

infection using systems biology approaches. By analyzing clinical data and blood specimens collected from a 

well-characterized, prospective cohort of Malian children who differ in their degree of immunity to P. falciparum

infection, the candidate will address two main research aims: 1) determine immune parameters predictive of 

protection from symptomatic infection (clinical immunity) and protection from P. falciparum infection (sterile 

immunity) and 2) relate these immune parameters and outcomes to the ability of plasma obtained from these

children to inhibit parasite invasion into liver and red blood cells in vitro. The practical implications of this work 

include identifying novel immune predictors and mechanisms of protection from P. falciparum infection and 

disease within the vaccine target population that could provide rational benchmarks for candidate malaria 

vaccines.

 

The candidate is firmly committed to a career in translational malaria research and systems biology and is 

strongly supported in his career and research goals by his mentors and his division at the Indiana University 

School of Medicine. He currently holds a position as an Assistant Professor of Medicine with 80% protected 

time for research, independent laboratory and office space, and funding for equipment. The current proposal 

includes a comprehensive mentorship and didactic plan to advance the candidate’s skills and knowledge in 

biostatistics and computational biology required for developing expertise in systems biology. Under the 

guidance of his primary mentor, Dr. Chandy John, and his co-mentors, Dr. Wanzhu Tu, Dr. Lang Li, and Dr. 

Peter Crompton, he will advance his bioinformatics skills and learn predictive modeling methodologies that will 

be directly applied to this proposal. Completion of this comprehensive training plan will provide the candidate 

with the skills and experience necessary to become a successful independent investigator specializing in 

computational systems biology with a focus on host immunity to Plasmodium infection.

 

Contact PD/PI: Tran, Tuan Manh

Project Summary/Abstract Page 6
Project Narrative

Each year malaria afflicts ~200 million people and causes over 430,000 deaths, primarily among African 

infants. Although a first-generation malaria vaccine is now available, it is only modestly effective in the target 

population of African infants; thus, a better understanding of natural immunity to Plasmodium falciparum, the 

deadliest of malaria parasites, in young African children can inform efforts to develop the next generation of 

malaria vaccines. Using samples collected from young Malian children before and during natural P. falciparum

infections, this study aims to identify predictors and mechanisms of malaria immunity that aid the development

of future malaria vaccines. 

Contact PD/PI: Tran, Tuan Manh

Project Narrative Page 7
References 

1. World Health Organization. World Malaria Report 2015: World Health Organization; 2015.

2. Rts SCTP. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants

and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet.

2015;386(9988):31-45. doi: 10.1016/S0140-6736(15)60721-8. PubMed PMID: 25913272.

3. Moreno A, Joyner C. Malaria vaccine clinical trials: what's on the horizon. Current opinion in i

mmunology. 2015;35:98-106. doi: 10.1016/j.coi.2015.06.008. PubMed PMID: 26172291.

4. Cohen S, Mc GI, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature.

1961;192:733-7. PubMed PMID: 13880318.

5. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, Chantavanich P, Foucault C,

Chongsuphajaisiddhi T, Druilhe P. Parasitologic and clinical human response to immunoglobulin

administration in falciparum malaria. The American journal of tropical medicine and hygiene.

1991;45(3):297-308. PubMed PMID: 1928564.

6. Stanisic DI, Barry AE, Good MF. Escaping the immune system: How the malaria parasite makes

vaccine development a challenge. Trends in parasitology. 2013;29(12):612-22. doi:

10.1016/j.pt.2013.10.001. PubMed PMID: 24176554.

7. Tran TM, Li S, Doumbo S, Doumtabe D, Huang CY, Dia S, Bathily A, Sangala J, Kone Y, Traore A,

Niangaly M, Dara C, Kayentao K, Ongoiba A, Doumbo OK, Traore B, Crompton PD. An intensive

longitudinal cohort study of Malian children and adults reveals no evidence of acquired immunity to

Plasmodium falciparum infection. Clinical infectious diseases : an official publication of the Infectious

Diseases Society of America. 2013;57(1):40-7. doi: 10.1093/cid/cit174. PubMed PMID: 23487390;

PMCID: 3669526.

8. Tran TM, Samal B, Kirkness E, Crompton PD. Systems immunology of human malaria. Trends in

parasitology. 2012;28(6):248-57. doi: 10.1016/j.pt.2012.03.006. PubMed PMID: 22592005; PMCID:

3361535.

9. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, Pirani A, Gernert K, Deng J, Marzolf

B, Kennedy K, Wu H, Bennouna S, Oluoch H, Miller J, Vencio RZ, Mulligan M, Aderem A, Ahmed R,

Pulendran B. Systems biology approach predicts immunogenicity of the yellow fever vaccine in

humans. Nature immunology. 2009;10(1):116-25. doi: 10.1038/ni.1688. PubMed PMID: 19029902;

PMCID: PMC4049462.

10. Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, Haining WN, Means AR, Kasturi SP,

Khan N, Li GM, McCausland M, Kanchan V, Kokko KE, Li S, Elbein R, Mehta AK, Aderem A, Subbarao

K, Ahmed R, Pulendran B. Systems biology of vaccination for seasonal influenza in humans. Nature

immunology. 2011;12(8):786-95. doi: 10.1038/ni.2067. PubMed PMID: 21743478; PMCID:

PMC3140559.

11. Tsang JS, Schwartzberg PL, Kotliarov Y, Biancotto A, Xie Z, Germain RN, Wang E, Olnes MJ,

Narayanan M, Golding H, Moir S, Dickler HB, Perl S, Cheung F, Baylor HC, Consortium CHI. Global

analyses of human immune variation reveal baseline predictors of postvaccination responses. Cell.

2014;157(2):499-513. doi: 10.1016/j.cell.2014.03.031. PubMed PMID: 24725414; PMCID:

PMC4139290.

12. Li S, Rouphael N, Duraisingham S, Romero-Steiner S, Presnell S, Davis C, Schmidt DS, Johnson SE,

Milton A, Rajam G, Kasturi S, Carlone GM, Quinn C, Chaussabel D, Palucka AK, Mulligan MJ, Ahmed

R, Stephens DS, Nakaya HI, Pulendran B. Molecular signatures of antibody responses derived from a

systems biology study of five human vaccines. Nature immunology. 2014;15(2):195-204. doi:

10.1038/ni.2789. PubMed PMID: 24336226; PMCID: PMC3946932.

13. Zaas AK, Chen M, Varkey J, Veldman T, Hero AO, 3rd, Lucas J, Huang Y, Turner R, Gilbert A,

Lambkin-Williams R, Oien NC, Nicholson B, Kingsmore S, Carin L, Woods CW, Ginsburg GS. Gene

expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans.

Cell host & microbe. 2009;6(3):207-17. doi: 10.1016/j.chom.2009.07.006. PubMed PMID: 19664979;

PMCID: PMC2852511.

14. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, Wilkinson KA, Banchereau R, Skinner J,

Wilkinson RJ, Quinn C, Blankenship D, Dhawan R, Cush JJ, Mejias A, Ramilo O, Kon OM, Pascual V,

Banchereau J, Chaussabel D, O'Garra A. An interferon-inducible neutrophil-driven blood transcriptional

signature in human tuberculosis. Nature. 2010;466(7309):973-7. doi: 10.1038/nature09247. PubMed

PMID: 20725040; PMCID: PMC3492754.

Contact PD/PI: Tran, Tuan Manh

References Cited Page 8
15. Anderson ST, Kaforou M, Brent AJ, Wright VJ, Banwell CM, Chagaluka G, Crampin AC, Dockrell HM, 

French N, Hamilton MS, Hibberd ML, Kern F, Langford PR, Ling L, Mlotha R, Ottenhoff TH, Pienaar S, 

Pillay V, Scott JA, Twahir H, Wilkinson RJ, Coin LJ, Heyderman RS, Levin M, Eley B, Consortium I, 

Group KTS. Diagnosis of childhood tuberculosis and host RNA expression in Africa. The New England 

journal of medicine. 2014;370(18):1712-23. doi: 10.1056/NEJMoa1303657. PubMed PMID: 24785206; 

PMCID: PMC4069985. 

16. Portugal S, Moebius J, Skinner J, Doumbo S, Doumtabe D, Kone Y, Dia S, Kanakabandi K, Sturdevant 

DE, Virtaneva K, Porcella SF, Li S, Doumbo OK, Kayentao K, Ongoiba A, Traore B, Crompton PD. 

Exposure-dependent control of malaria-induced inflammation in children. PLoS pathogens. 

2014;10(4):e1004079. doi: 10.1371/journal.ppat.1004079. PubMed PMID: 24743880; PMCID: 

PMC3990727. 

17. Tran TM, Ongoiba A, Coursen J, Crosnier C, Diouf A, Huang CY, Li S, Doumbo S, Doumtabe D, Kone 

Y, Bathily A, Dia S, Niangaly M, Dara C, Sangala J, Miller LH, Doumbo OK, Kayentao K, Long CA, 

Miura K, Wright GJ, Traore B, Crompton PD. Naturally acquired antibodies specific for Plasmodium 

falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from 

malaria. The Journal of infectious diseases. 2014;209(5):789-98. doi: 10.1093/infdis/jit553. PubMed 

PMID: 24133188; PMCID: 3923542. 

18. Doumbo S, Tran TM, Sangala J, Li S, Doumtabe D, Kone Y, Traore A, Bathily A, Sogoba N, Coulibaly 

ME, Huang CY, Ongoiba A, Kayentao K, Diallo M, Dramane Z, Nutman TB, Crompton PD, Doumbo O, 

Traore B. Co-infection of long-term carriers of Plasmodium falciparum with Schistosoma haematobium 

enhances protection from febrile malaria: a prospective cohort study in Mali. PLoS neglected tropical 

diseases. 2014;8(9):e3154. doi: 10.1371/journal.pntd.0003154. PubMed PMID: 25210876; PMCID: 

PMC4161351. 

19. Verlander JW, Tran TM, Zhang L, Kaplan MR, Hebert SC. Estradiol enhances thiazide-sensitive NaCl 

cotransporter density in the apical plasma membrane of the distal convoluted tubule in ovariectomized 

rats. The Journal of clinical investigation. 1998;101(8):1661-9. doi: 10.1172/JCI601. PubMed PMID: 

9541496; PMCID: 508747.

20. Lima-Junior JC, Banic DM, Tran TM, Meyer VS, De-Simone SG, Santos F, Porto LC, Marques MT, 

Moreno A, Barnwell JW, Galinski MR, Oliveira-Ferreira J. Promiscuous T-cell epitopes of Plasmodium 

merozoite surface protein 9 (PvMSP9) induces IFN-gamma and IL-4 responses in individuals naturally 

exposed to malaria in the Brazilian Amazon. Vaccine. 2010;28(18):3185-91. doi: 

10.1016/j.vaccine.2010.02.046. PubMed PMID: 20189487; PMCID: 2861348. 

21. Lima-Junior JC, Tran TM, Meyer EV, Singh B, De-Simone SG, Santos F, Daniel-Ribeiro CT, Moreno A, 

Barnwell JW, Galinski MR, Oliveira-Ferreira J. Naturally acquired humoral and cellular immune 

responses to Plasmodium vivax merozoite surface protein 9 in Northwestern Amazon individuals. 

Vaccine. 2008;26(51):6645-54. doi: 10.1016/j.vaccine.2008.09.029. PubMed PMID: 18832003. 

22. Tran TM. Evaluation of the Plasmodium vivax reticulocyte binding protein 1 as a vaccine candidate. 

Atlanta, GA: Emory University; 2005. 

23. Tran TM, Moreno A, Yazdani SS, Chitnis CE, Barnwell JW, Galinski MR. Detection of a Plasmodium 

vivax erythrocyte binding protein by flow cytometry. Cytometry Part A : the journal of the International 

Society for Analytical Cytology. 2005;63(1):59-66. doi: 10.1002/cyto.a.20098. PubMed PMID: 

15584018.

24. Tran TM, Oliveira-Ferreira J, Moreno A, Santos F, Yazdani SS, Chitnis CE, Altman JD, Meyer EV, 

Barnwell JW, Galinski MR. Comparison of IgG reactivities to Plasmodium vivax merozoite invasion 

antigens in a Brazilian Amazon population. The American journal of tropical medicine and hygiene. 

2005;73(2):244-55. PubMed PMID: 16103583. 

25. Rayner JC, Tran TM, Corredor V, Huber CS, Barnwell JW, Galinski MR. Dramatic difference in diversity 

between Plasmodium falciparum and Plasmodium vivax reticulocyte binding-like genes. The American 

journal of tropical medicine and hygiene. 2005;72(6):666-74. PubMed PMID: 15964948. 

26. Yilmaz B, Portugal S, Tran TM, Gozzelino R, Ramos S, Gomes J, Regalado A, Cowan PJ, d'Apice AJ, 

Chong AS, Doumbo OK, Traore B, Crompton PD, Silveira H, Soares MP. Gut microbiota elicits a 

protective immune response against malaria transmission. Cell. 2014;159(6):1277-89. doi: 

10.1016/j.cell.2014.10.053. PubMed PMID: 25480293; PMCID: PMC4261137. 

27. Arama C, Skinner J, Doumtabe D, Portugal S, Tran TM, Jain A, Traore B, Doumbo OK, Davies DH, 

Troye-Blomberg M, Dolo A, Felgner PL, Crompton PD. Genetic Resistance to Malaria Is Associated 

With Greater Enhancement of Immunoglobulin (Ig)M Than IgG Responses to a Broad Array of 

Contact PD/PI: Tran, Tuan Manh

References Cited Page 9
Plasmodium falciparum Antigens. Open Forum Infect Dis. 2015;2(3):ofv118. doi: 10.1093/ofid/ofv118. 

PubMed PMID: 26361633; PMCID: PMC4564391. 

28. Banga S, Coursen JD, Portugal S, Tran TM, Hancox L, Ongoiba A, Traore B, Doumbo OK, Huang CY, 

Harty JT, Crompton PD. Impact of acute malaria on pre-existing antibodies to viral and vaccine 

antigens in mice and humans. PloS one. 2015;10(4):e0125090. doi: 10.1371/journal.pone.0125090. 

PubMed PMID: 25919588; PMCID: PMC4412709. 

29. Gordon EB, Hart GT, Tran TM, Waisberg M, Akkaya M, Kim AS, Hamilton SE, Pena M, Yazew T, 

Chen-Feng Q, Chen-Fang L, Ying-Chun L, Miller LH, Powell JD, Pierce SK. Targeting glutamine 

metabolism rescues mice from late-stage cerebral malaria. Proc Natl Acad Sci U S A. 2015;In Press. 

30. Gordon EB, Hart GT, Tran TM, Waisberg M, Akkaya M, Skinner J, Zinocker S, Pena M, Yazew T, Qi 

CF, Miller LH, Pierce SK. Inhibiting the Mammalian target of rapamycin blocks the development of 

experimental cerebral malaria. mBio. 2015;6(3). doi: 10.1128/mBio.00725-15. PubMed PMID: 

26037126; PMCID: 4453009.

31. Obeng-Adjei N, Portugal S, Tran TM, Yazew TB, Skinner J, Li S, Jain A, Felgner PL, Ongoiba A, Traore 

B, Crompton PD. Circulating Th1 cell-type Tfh cells that exhibit impaired B cell help are preferentially 

activated during acute malaria in children. Cell reports. 2015. Epub In press. 

32. Yooseph S, Kirkness EF, Tran TM, Harkins DM, Jones MB, Torralba MG, O'Connell E, Nutman TB, 

Doumbo S, Doumbo OK, Traore B, Crompton PD, Nelson KE. Stool microbiota composition is 

associated with the prospective risk of Plasmodium falciparum infection. BMC Genomics. 

2015;16(1):631. doi: 10.1186/s12864-015-1819-3. PubMed PMID: 26296559; PMCID: PMC4546150. 

33. Tran TM, Ongoiba A, Jones M, Skinner J, Li S, Doumbo S, Doumtabe D, Kone Y, Bathily A, Sangala J, 

Doumbo OK, Venepally P, Kayentao K, Traore B, Kirkness EF, Crompton PD. 128A whole-blood 

transcriptional signature predicts parasite control and protection from malaria fever during natural 

Plasmodium falciparum infection. Open Forum Infectious Diseases. 2014;1(suppl 1):S13. doi: 

10.1093/ofid/ofu051.36. 

34. Nosten F, Luxemburger C, Kyle DE, Ballou WR, Wittes J, Wah E, Chongsuphajaisiddhi T, Gordon DM, 

White NJ, Sadoff JC, Heppner DG. Randomised double-blind placebo-controlled trial of SPf66 malaria 

vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet. 

1996;348(9029):701-7. PubMed PMID: 8806288. 

35. Rts SCTP, Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, Adegnika 

AA, Mordmuller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Machevo S, 

Acacio S, Bulo H, Sigauque B, Macete E, Alonso P, Abdulla S, Salim N, Minja R, Mpina M, Ahmed S, 

Ali AM, Mtoro AT, Hamad AS, Mutani P, Tanner M, Tinto H, D'Alessandro U, Sorgho H, Valea I, Bihoun 

B, Guiraud I, Kabore B, Sombie O, Guiguemde RT, Ouedraogo JB, Hamel MJ, Kariuki S, Oneko M, 

Odero C, Otieno K, Awino N, McMorrow M, Muturi-Kioi V, Laserson KF, Slutsker L, Otieno W, Otieno L, 

Otsyula N, Gondi S, Otieno A, Owira V, Oguk E, Odongo G, Woods JB, Ogutu B, Njuguna P, Chilengi 

R, Akoo P, Kerubo C, Maingi C, Lang T, Olotu A, Bejon P, Marsh K, Mwambingu G, Owusu-Agyei S, 

Asante KP, Osei-Kwakye K, Boahen O, Dosoo D, Asante I, Adjei G, Kwara E, Chandramohan D, 

Greenwood B, Lusingu J, Gesase S, Malabeja A, Abdul O, Mahende C, Liheluka E, Malle L, Lemnge 

M, Theander TG, Drakeley C, Ansong D, Agbenyega T, Adjei S, Boateng HO, Rettig T, Bawa J, 

Sylverken J, Sambian D, Sarfo A, Agyekum A, Martinson F, Hoffman I, Mvalo T, Kamthunzi P, Nkomo 

R, Tembo T, Tegha G, Tsidya M, Kilembe J, Chawinga C, Ballou WR, Cohen J, Guerra Y, Jongert E, 

Lapierre D, Leach A, Lievens M, Ofori-Anyinam O, Olivier A, Vekemans J, Carter T, Kaslow D, 

Leboulleux D, Loucq C, Radford A, Savarese B, Schellenberg D, Sillman M, Vansadia P. A phase 3 

trial of RTS,S/AS01 malaria vaccine in African infants. The New England journal of medicine. 

2012;367(24):2284-95. doi: 10.1056/NEJMoa1208394. PubMed PMID: 23136909. 

36. Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, Kone AK, Guindo AB, Traore K, Traore 

I, Kouriba B, Diallo DA, Diarra I, Daou M, Dolo A, Tolo Y, Sissoko MS, Niangaly A, Sissoko M, TakalaHarrison S, Lyke KE, Wu Y, Blackwelder WC, Godeaux O, Vekemans J, Dubois MC, Ballou WR, 

Cohen J, Thompson D, Dube T, Soisson L, Diggs CL, House B, Lanar DE, Dutta S, Heppner DG, Jr., 

Plowe CV. A field trial to assess a blood-stage malaria vaccine. The New England journal of medicine. 

2011;365(11):1004-13. doi: 10.1056/NEJMoa1008115. PubMed PMID: 21916638; PMCID: 3242358. 

37. Fessenden M. The cell menagerie: human immune profiling. Nature. 2015;525(7569):409-11. doi: 

10.1038/525409a. PubMed PMID: 26381986. 

38. Plucinski MM, Guilavogui T, Sidikiba S, Diakite N, Diakite S, Dioubate M, Bah I, Hennessee I, Butts JK, 

Halsey ES, McElroy PD, Kachur SP, Aboulhab J, James R, Keita M. Effect of the Ebola-virus-disease 

Contact PD/PI: Tran, Tuan Manh

References Cited Page 10
epidemic on malaria case management in Guinea, 2014: a cross-sectional survey of health facilities. 

The Lancet infectious diseases. 2015. doi: 10.1016/S1473-3099(15)00061-4. PubMed PMID: 

26116183.

39. Severe malaria. Trop Med Int Health. 2014;19 Suppl 1:7-131. doi: 10.1111/tmi.12313_2. PubMed 

PMID: 25214480. 

40. Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to malaria: more questions than answers. 

Nature immunology. 2008;9(7):725-32. Epub 2008/06/20. doi: 10.1038/ni.f.205. PubMed PMID: 

18563083.

41. Reece WH, Pinder M, Gothard PK, Milligan P, Bojang K, Doherty T, Plebanski M, Akinwunmi P, 

Everaere S, Watkins KR, Voss G, Tornieporth N, Alloueche A, Greenwood BM, Kester KE, McAdam 

KP, Cohen J, Hill AV. A CD4(+) T-cell immune response to a conserved epitope in the 

circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and 

disease. Nature medicine. 2004;10(4):406-10. doi: 10.1038/nm1009. PubMed PMID: 15034567. 

42. Olotu A, Moris P, Mwacharo J, Vekemans J, Kimani D, Janssens M, Kai O, Jongert E, Lievens M, 

Leach A, Villafana T, Savarese B, Marsh K, Cohen J, Bejon P. Circumsporozoite-specific T cell 

responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical 

malaria. PloS one. 2011;6(10):e25786. doi: 10.1371/journal.pone.0025786. PubMed PMID: 21998698; 

PMCID: PMC3188575. 

43. D'Ombrain MC, Robinson LJ, Stanisic DI, Taraika J, Bernard N, Michon P, Mueller I, Schofield L. 

Association of early interferon-gamma production with immunity to clinical malaria: a longitudinal study 

among Papua New Guinean children. Clinical infectious diseases : an official publication of the 

Infectious Diseases Society of America. 2008;47(11):1380-7. doi: 10.1086/592971. PubMed PMID: 

18947328.

44. Schofield L, Villaquiran J, Ferreira A, Schellekens H, Nussenzweig R, Nussenzweig V. Gamma i

 nterferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature. 

1987;330(6149):664-6. doi: 10.1038/330664a0. PubMed PMID: 3120015. 

45. Ferreira A, Schofield L, Enea V, Schellekens H, van der Meide P, Collins WE, Nussenzweig RS, 

Nussenzweig V. Inhibition of development of exoerythrocytic forms of malaria parasites by gammainterferon. Science. 1986;232(4752):881-4. PubMed PMID: 3085218. 

46. Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, Laurens MB, Gunasekera A, Chakravarty S, 

James ER, Sedegah M, Richman A, Velmurugan S, Reyes S, Li M, Tucker K, Ahumada A, Ruben AJ, 

Li T, Stafford R, Eappen AG, Tamminga C, Bennett JW, Ockenhouse CF, Murphy JR, Komisar J, 

Thomas N, Loyevsky M, Birkett A, Plowe CV, Loucq C, Edelman R, Richie TL, Seder RA, Hoffman SL. 

Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science. 

2011;334(6055):475-80. doi: 10.1126/science.1211548. PubMed PMID: 21903775. 

47. Liehl P, Zuzarte-Luis V, Chan J, Zillinger T, Baptista F, Carapau D, Konert M, Hanson KK, Carret C, 

Lassnig C, Muller M, Kalinke U, Saeed M, Chora AF, Golenbock DT, Strobl B, Prudencio M, Coelho LP, 

Kappe SH, Superti-Furga G, Pichlmair A, Vigario AM, Rice CM, Fitzgerald KA, Barchet W, Mota MM. 

Host-cell sensors for Plasmodium activate innate immunity against liver-stage infection. Nature 

medicine. 2014;20(1):47-53. doi: 10.1038/nm.3424. PubMed PMID: 24362933; PMCID: 4096771. 

48. Miller JL, Sack BK, Baldwin M, Vaughan AM, Kappe SH. Interferon-mediated innate immune responses 

against malaria parasite liver stages. Cell reports. 2014;7(2):436-47. doi: 10.1016/j.celrep.2014.03.018. 

PubMed PMID: 24703850. 

49. Males S, Gaye O, Garcia A. Long-term asymptomatic carriage of Plasmodium falciparum protects from 

malaria attacks: a prospective study among Senegalese children. Clinical infectious diseases : an 

official publication of the Infectious Diseases Society of America. 2008;46(4):516-22. Epub 2008/01/18. 

doi: 10.1086/526529. PubMed PMID: 18199040. 

50. Hofmann N, Mwingira F, Shekalaghe S, Robinson LJ, Mueller I, Felger I. Ultra-sensitive detection of 

Plasmodium falciparum by amplification of multi-copy subtelomeric targets. PLoS medicine. 

2015;12(3):e1001788. doi: 10.1371/journal.pmed.1001788. PubMed PMID: 25734259; PMCID: 

PMC4348198. 

51. Coulibaly D, Diallo DA, Thera MA, Dicko A, Guindo AB, Kone AK, Cissoko Y, Coulibaly S, Djimde A, 

Lyke K, Doumbo OK, Plowe CV. Impact of preseason treatment on incidence of falciparum malaria and 

parasite density at a site for testing malaria vaccines in Bandiagara, Mali. The American journal of 

tropical medicine and hygiene. 2002;67(6):604-10. PubMed PMID: 12518850. 

Contact PD/PI: Tran, Tuan Manh

References Cited Page 11
52. Roll Back Malaria Partnership. Global malaria action plan. Available from: 

http://www.rbm.who.int/gmap/. 

53. Rizzo C, Ronca R, Fiorentino G, Mangano VD, Sirima SB, Nebie I, Petrarca V, Modiano D, Arca B. 

Wide cross-reactivity between Anopheles gambiae and Anopheles funestus SG6 salivary proteins 

supports exploitation of gSG6 as a marker of human exposure to major malaria vectors in tropical 

Africa. Malaria journal. 2011;10:206. doi: 10.1186/1475-2875-10-206. PubMed PMID: 21794142; 

PMCID: PMC3160432. 

54. Lopera-Mesa TM, Doumbia S, Konate D, Anderson JM, Doumbouya M, Keita AS, Diakite SA, Traore K, 

Krause MA, Diouf A, Moretz SE, G ST, Miura K, Gu W, Fay MP, Taylor SM, Long CA, Diakite M, 

Fairhurst RM. Impact of red blood cell variants on childhood malaria in Mali: a prospective cohort study. 

Lancet Haematol. 2015;2(4):e140-e9. doi: 10.1016/S2352-3026(15)00043-5. PubMed PMID: 

25954766; PMCID: PMC4418020. 

55. Crompton PD, Traore B, Kayentao K, Doumbo S, Ongoiba A, Diakite SA, Krause MA, Doumtabe D, 

Kone Y, Weiss G, Huang CY, Doumbia S, Guindo A, Fairhurst RM, Miller LH, Pierce SK, Doumbo OK. 

Sickle cell trait is associated with a delayed onset of malaria: implications for time-to-event analysis in 

clinical studies of malaria. The Journal of infectious diseases. 2008;198(9):1265-75. Epub 2008/08/30. 

doi: 10.1086/592224. PubMed PMID: 18752444; PMCID: 2574881. 

56. Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario VE, Thaithong S, Brown KN. High 

sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. 

Molecular and biochemical parasitology. 1993;61(2):315-20. Epub 1993/10/01. PubMed PMID: 

8264734.

57. Obeng-Adjei N, Portugal S, Tran TM, Yazew TB, Skinner J, Li S, Jain A, Felgner PL, Doumbo OK, 

Kayentao K, Ongoiba A, Traore B, Crompton PD. Circulating Th1-Cell-type Tfh Cells that Exhibit 

Impaired B Cell Help Are Preferentially Activated during Acute Malaria in Children. Cell reports. 

2015;13(2):425-39. doi: 10.1016/j.celrep.2015.09.004. PubMed PMID: 26440897; PMCID: 

PMC4607674. 

58. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression 

analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi: 

10.1093/nar/gkv007. PubMed PMID: 25605792; PMCID: PMC4402510. 

59. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression 

analysis of digital gene expression data. Bioinformatics. 2010;26(1):139-40. doi: 

10.1093/bioinformatics/btp616. PubMed PMID: 19910308; PMCID: PMC2796818. 

60. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data 

with DESeq2. Genome Biol. 2014;15(12):550. doi: 10.1186/s13059-014-0550-8. PubMed PMID: 

25516281; PMCID: PMC4302049.

61. Wu H, Wang C, Wu Z. PROPER: comprehensive power evaluation for differential expression using 

RNA-seq. Bioinformatics. 2015;31(2):233-41. doi: 10.1093/bioinformatics/btu640. PubMed PMID: 

25273110; PMCID: PMC4287952.

62. Zou H, Hastie T. Regularization and variable selection via the elastic net. Journal of the Royal 

Statistical Society: Series B (Statistical Methodology). 2005;67(2):301-20. doi: 10.1111/j.1467-

9868.2005.00503.x. 

63. Wammes LJ, Wiria AE, Toenhake CG, Hamid F, Liu KY, Suryani H, Kaisar MM, Verweij JJ, Sartono E, 

Supali T, Smits HH, Luty AJ, Yazdanbakhsh M. Asymptomatic plasmodial infection is associated with 

increased tumor necrosis factor receptor II-expressing regulatory T cells and suppressed type 2 

immune responses. The Journal of infectious diseases. 2013;207(10):1590-9. doi: 10.1093/infdis/jit058. 

PubMed PMID: 23408847. 

64. de Mast Q, Brouwers J, Syafruddin D, Bousema T, Baidjoe AY, de Groot PG, van der Ven AJ, Fijnheer 

R. Is asymptomatic malaria really asymptomatic? Hematological, vascular and inflammatory effects of 

asymptomatic malaria parasitemia. J Infect. 2015. doi: 10.1016/j.jinf.2015.08.005. PubMed PMID: 

26304688.

65. March S, Ng S, Velmurugan S, Galstian A, Shan J, Logan DJ, Carpenter AE, Thomas D, Sim BK, Mota 

MM, Hoffman SL, Bhatia SN. A microscale human liver platform that supports the hepatic stages of 

Plasmodium falciparum and vivax. Cell host & microbe. 2013;14(1):104-15. doi: 

10.1016/j.chom.2013.06.005. PubMed PMID: 23870318; PMCID: PMC3780791. 

66. March S, Ramanan V, Trehan K, Ng S, Galstian A, Gural N, Scull MA, Shlomai A, Mota MM, Fleming 

HE, Khetani SR, Rice CM, Bhatia SN. Micropatterned coculture of primary human hepatocytes and 

Contact PD/PI: Tran, Tuan Manh

References Cited Page 12
supportive cells for the study of hepatotropic pathogens. Nat Protoc. 2015;10(12):2027-53. doi: 

10.1038/nprot.2015.128. PubMed PMID: 26584444. 

67. Khatri P, Sirota M, Butte AJ. Ten years of pathway analysis: current approaches and outstanding 

challenges. PLoS Comput Biol. 2012;8(2):e1002375. doi: 10.1371/journal.pcbi.1002375. PubMed 

PMID: 22383865; PMCID: PMC3285573. 

Contact PD/PI: Tran, Tuan Manh

References Cited Page 13
Facilities and Resources

Overview: IUSM was established in 1903, graduating its first class in 1907, and merged with other 

Indianapolis schools to form Indiana University – Purdue University Indianapolis (IUPUI) in 1969. The main 

medical center campus, located at IUPUI, occupies 93 acres in downtown Indianapolis and consists of 18 

buildings and four hospitals: University, Eskenazi Health, Roudebush Veteran’s Administration, and the James 

Whitcomb Riley Hospital for Children. A fifth downtown hospital, the not-for-profit Methodist Hospital, merged 

with Indiana University Hospital in 1997 to form Indiana University Health. Within IUSM facilities, research 

laboratory and support space encompasses approximately 619,000 net assignable square feet. An additional 

41,000 net assignable square feet of IUSM-leased lab space is located off campus at partner health 

institutions. The academic faculty comprises of ~2,000 full-time faculty across more than 60 clinical 

departments and 29 research institutes. For FY2014-15, IUSM received approximately $302 million in 

sponsored programs funding, $111 million of which came from the NIH. As of June 2015, there were 564 

externally funded primary investigators at IUSM. IUSM currently hosts 12 research centers or program 

projects supported by PHS/NIH or other federal funds, and at least 20 supported by non-federal funds. As of

June 2015, there were 14 T32, one T35, three R25, one CTSI-based (TL1), eight HRSA, nine F-series, and 18 

K-series federally-funded training programs and grants at IUSM. 

 

Laboratory: The IU Cancer Research Institute (R4) at IUSM is a four-story, 112,000 square foot research and 

teaching facility that houses the Herman B. Wells Center for Pediatric Research and laboratories for 

researchers from seven multidisciplinary research groups. I have 500 square feet independent laboratory 

space (R4 Room 451B) adjacent to the laboratory of Dr. Chandy John, my primary mentor, which features 

shared biosafety cabinets and incubators for tissue culture work and a liquid nitrogen storage tower. My 

laboratory is equipped with: a -80°C freezer, a -20°C freezer/refrigerator, a refrigerated Eppendorf 5430R 

centrifuge, an Eppendorf 5424 centrifuge, a microwave, water baths, a heat block, Mettler-Toledo scale, 

vortexes, a Qubit 3.0 Fluorometer, a mini-incubator, a BioTek 96-well plate washer with magnetic adapter, a 

Bio-Rad C1000 Touch thermal cycler, and an upright and inverted phase microscope. A Bio-Rad MAGPIX 

multiplex reader for bead-based immunoassays, ELISA microplate reader, Bio-Rad plate washer, a LabChip 

GX Touch HT microfluidic device, a Bio-Rad Tetrad Thermal Cycler, and an Applied Biosystems QuantStudio 6 

Flex Real-Time PCR System with 96- and 384-well blocks will be shared with Dr. John. The Wells Center also 

provides glass washing, common reagent preparation, and sterilization services for all investigators. As a 

member of the Wells Center, I will have unlimited access to a BD FACSCanto II capable of 6-color flow 

cytometer for routine FACS experiments. Importantly, R4 is adjacent to Walther Hall, which houses the flowcytometry core facilities within the IU Simon Cancer Center, allowing access to the necessary equipment for 

conducting multi-parametric flow cytometry assays and cell sorting experiments (see below). 

Clinical sites: IUSM and its affiliated hospitals are located on or near the IUPUI campus. The main campus 

complex is 93 acres in area. IU Health manages the administration of three of the teaching hospitals 

(University Hospital, Riley Hospital for Children, and Methodist Hospital). The School is nearly physically 

contiguous with the Richard L. Roudebush Veterans Administration Medical Center located less than 1⁄4 mile 

from the western edge of campus. University Hospital is a tertiary care hospital and referral center for Indiana 

and nearby states. It has approximately 400 inpatient beds. Methodist Hospital has approximately 800 beds 

and was formerly an independent non-profit hospital. Methodist Hospital also has a full range of tertiary 

services including: Level 1 trauma Center, orthopedics, cardiovascular, neurosciences and outpatient surgery.

I will devote no more than 20% effort to clinical responsibilities. I will maintain a one half-day Infectious 

Diseases clinic every other week at the Indiana University Hospital Medical Diagnostic Center, focusing on 

patients with infectious diseases issues who need urgent appointments, timely hospital follow up, or travel 

medicine consultation. I will also provide 6 weeks of clinical service per year as the Infectious Diseases consult 

attending at Methodist, University, or Roudebush Hospitals.

Offices: I have a fully furnished office within the Wells Center in the Cancer Research Building (R4) on the 

same floor as my laboratory with a personal phone, computer, and printer, and internet access. Print, copy, 

scan, and fax capabilities are provided by a shared laboratory multi-function printer. My office is along the 

same hallway as the primary office of Dr. John. I also have an office in the Van Nuys Medical Science Building 

in the Division of Infectious Diseases within the Department of Medicine, with a separate phone, computer, and 

Contact PD/PI: Tran, Tuan Manh

Facilities & Other Resources Page 14
shared printer, in close proximity to the office of my Division Director Dr. Kara Wools-Kaloustian (located in 

Emerson Hall). 

Computers: I will be using a 15-inch MacBook Pro with a 2.8 GHZ Quad-core Intel Core i7 processor and a 

MacPro with a 3.5GHz 6-Core Intel Xeon E5 processor as primary research computers, equipped with external 

Dell 24” P2416D monitors. Appropriate software will be installed on the computer, including Microsoft Office, 

EndNote, R, GraphPad Prism, Adobe Illustrator, Adobe Acrobat, FlowJo, and Ingenuity Pathways Analysis. In 

addition, I have an iMac in my Medical Science Building office, which I use primarily for clinical work, and an 

iMac for use by a laboratory technician. A Dell Optiplex 9020 will be a common-use computer in my laboratory 

dedicated to running Windows-only applications such as ABI PeakScanner and SDS software packages. I 

maintain an NIH/NIAID MacBook Pro laptop through my Special Volunteer status at the NIH, in conjunction 

with my co-mentor Dr. Crompton, allowing access to an encrypted NIH server for collaborative work. The 

computers at IUSM are connected via Ethernet or secured Wi-Fi to the main server for email, Internet access, 

and secure storage of data files. Research data is backed up from the servers to on-site disk backup devices 

using 256-bit AES encryption.

The IUSM Center for Computational Biology and Bioinformatics (CCBB) can provide additional 

computational support. Statistical packages include R, SAS, S-PLUS, SigmaPlot, nQuery Advisor, DBMScopy, 

Solas, LogXact, StatXact, and SPSS. Databases are implemented using Microsoft SQL Server 2000. The 

center also maintains a network of UNIX systems, running Solaris or Linux for intensive data analysis. The 

staff accesses these UNIX machines over the network using Hummingbird Exceed or SSH. 

For statistical analysis requiring high-performance parallel computing, I will have access to the IU 

supercomputers, which include IU's Big Red II supercomputer (one petaflops), Big Red supercomputer (40.96 

teraflops), Quarry parallel computing cluster (26.22 teraflops), and Mason large-memory (8TB) computing 

cluster (3.81 teraflops).

Administrative support: The Division of Infectious Diseases provides administrative support for this project. 

The Department of Medicine provides support for website design and maintenance, grants management 

expertise, and appropriate laboratory and office space. In addition, the Department has a dedicated and 

engaged Vice Chair of Research Dr. Samir Gupta who provides career development support for junior faculty. 

Other Resources – Research Environment

IU Bloomington Center for Genomics and Bioinformatics: The Center for Genomics and Bioinformatics

(CGB), directed by Dr. Scott Michaels, offers in-house next generation sequencing services on Roche 454, 

Illumina NextSeq, and Illumina MiSeq platforms for IU faculty. Sequencing on Illumina HiSeq is also available 

via send out. CGB also provides RNA-seq mapping services, transcriptome annotation services, and sequence 

submission to the NCBI Sequence Read Archive and Gene Expression Omnibus.

IU Simon Cancer Center Flow Cytometry and Proteomics Services: As an investigator within the Wells 

Center, I have ready access to the necessary equipment for flow cytometry and cell sorting through the Flow 

Cytometry Core Facility at the IU Simon Cancer Center, located in Walther Hall, a building directly connected 

to R4. This facility contains two BD FACSCalibur (three and four colors) and two BD LSRII (nine and 10 

colors) flow cytometers as well as BD FACSAria (10 colors), BD SORP Aria (15 colors), and iCyt Reflection 

(nine colors) cell sorters. Both the FACSAria and SORP Aria are BSL2+. In addition, IUSM recently acquired a 

CyTOF2 Mass cytometer, which allows simultaneous detection of more than 40 parameters using metalconjugated markers at the single cell level.

University Libraries: As a member of IU faculty, I have access to nearly 700 databases, 60,000 electronic 

journal titles, and 815,000 electronic books. 

The IUPUI University Library is a state-of-the-art library completed in 1993. It houses more than one million 

volumes, including current subscriptions to over 35,000 print and electronic journals.

The Ruth Lilly Medical Library (RLML) was established in 1908 and is the largest academic health sciences 

library in Indiana. It is the primary information resource for faculty, students, and staff of the Indiana University 

Contact PD/PI: Tran, Tuan Manh

Facilities & Other Resources Page 15
School of Medicine and ancillary health sciences programs. The RLML has eight tenure-track library faculty, 

three non-tenure track librarians, and eight support staff members. The Library staff is available for 

consultation on a wide range of knowledge management issues and manages a collection of 8,000 electronic 

journals, 15,000 electronic books and nearly 200,000 print volumes.

Resources for Early Stage Investigators: IUSM is committed to promoting the development and 

advancement of early stage investigators and offers the following resources: 

A. The Indiana Clinical and Translational Sciences Institutes (CTSI) offers Young Investigator Awards in 

Clinical-Translational Research, of which I am a recipient. These awards designed to provide junior 

investigator faculty with the opportunity to be mentored in research-intensive multi-disciplinary settings toward 

the goal of developing clinical-translational research careers. Clinical research can include epidemiological 

studies, clinical trials, or other investigations involving human subjects.

B. The Independent Investigator Incubator (I3

), supported by the IUSM Transforming Research 

Initiative (TRI) in collaboration with the CTSI, develops junior faculty into successful researchers by providing

access to one-on-one time and professional coaching from a senior faculty "super-mentor" and support 

services such as a professional grant writer, administrative support, and a biostatistician.

C. The Leadership in Academic Medicine Program (LAMP), organized through the Office of Faculty of 

Affairs and Professional Development at IUSM, is a year-long, cohort-based faculty development and 

orientation program designed for faculty in the second and third years of their appointment.

D. The Indiana-CTSI Project Development Teams are committees of multi-disciplinary researchers who help

investigators develop concepts and hypotheses into translational research projects necessary for successful 

extramural grant submissions, providing access to protocol development, pilot funding, biostatistics support, 

IRB/regulatory support, and access to collaborators at IUPUI and other Indiana-CTSI institutions (IU, Purdue, 

and Notre Dame).

Collaborating sites: Human samples will be obtained from the NIH in collaboration with Dr. Peter Crompton at 

NIAID and with the support of Dr. Boubacar Traore in the MRTC in Mali. The laboratory of Dr. Philip L. Felgner 

within the Institute for Immunology, University of California, Irvine will support protein array studies. The 

Laboratory of Multiscale Regenerative Technologies, directed by Dr. Sangeeta Bhatia, will support studies 

involving the microscale human liver platform.

Contact PD/PI: Tran, Tuan Manh

Facilities & Other Resources Page 16
Major Equipment

Dr. Tran’s laboratory is equipped with four BSL2 biosafety cabinets shared with two other investigators at the 

Wells Center. His laboratory will also have the following: a -80°C freezer, a -20°C freezer/refrigerator, a 

refrigerated Eppendorf 5430R centrifuge, an Eppendorf 5424 centrifuge, a microwave, water baths, a heat 

block, Mettler-Toledo scale, vortexes, a Qubit 3.0 Fluorometer, a mini-incubator, a BioTek 96-well plate washer 

with magnetic adapter, a Bio-Rad C1000 Touch thermal cycler, and an upright and inverted phase microscope. 

Dr. Tran will share the following equipment with Dr. John: Bio-Rad MAGPIX multiplex reader for bead-based 

immunoassays, ELISA microplate reader, Bio-Rad plate washer, a LabChip GX Touch HT microfluidic device, 

a Bio-Rad Tetrad Thermal Cycler, and an Applied Biosystems QuantStudio 6 Flex Real-Time PCR System with 

96- and 384-well blocks. 

Laboratory Core within the Wells Center for Pediatric Research: Dr. Tran will have routine access to a BD 

FACSCanto II 6-color flow cytometer and an additional Applied Biosystems real-time PCR machine. Other

available equipment includes autoMACs cell separators, two NanoDrop 2000 Spectrophotometers, two 

Beckman ultracentrifuges, Leica conventional and GFP microscopes equipped with digital cameras, Z1 coulter 

counter, a Perkin-Elmer cell harvester and Top Count system, and double-deionizing water purification 

systems. There will be a walk-in 4°C cold room along the same hallway as Dr. Tran’s lab.

Flow Cytometry Core Facility at IU Simon Cancer Center: Walther Hall, adjacent to the Wells Center, 

houses the flow cytometry core facility, which is equipped with two BD FACSCalibur (3 and 4 colors) and two 

BD LSRII (9 and 10 colors) flow cytometers as well as BD FACSAria (10 colors), BD SORP Aria (15 colors), 

and iCyt Reflection (9 colors) cell sorters. Both the FACSAria and SORP Aria are BSL2+. In addition, IUSM 

recently acquired a CyTOF2 Mass cytometer, which allows simultaneous detection of more than 40 

parameters using metal-conjugated markers at the single cell level. Core services, available to all investigators 

at the Wells Center, include multi-parameter immunofluorescence analysis and cell sorting, single cell sorting, 

cell cycle analysis, and kinetic analysis. 

IU Bloomington Center of Genomics and Bioinformatics: Dr. Tran will work with the genomics and 

bioinformatics team at CGB for his next generation sequencing studies. Available NGS equipment includes: a)

Illumina NextSeq 500 b) Illumina MiSeq c) Roche 454. Bioinformatics specialists will also provide mapping and 

visualization of sequences for the projects outlined in the proposal.

IUSM Center for Computational Biology and Bioinformatics (CCBB): Dr. Tran will have access to 

additional computational support through the CCBB. The center maintains a network of UNIX systems, running 

Solaris or Linux for intensive data analysis. For statistical analysis requiring high-performance parallel 

computing, Dr. Tran can access the IU supercomputers, which include IU's Big Red II supercomputer (one 

petaflops), Big Red supercomputer (40.96 teraflops), Quarry parallel computing cluster (26.22 teraflops), and 

Mason large-memory (8TB) computing cluster (3.81 teraflops).

Contact PD/PI: Tran, Tuan Manh

Equipment Page 17
Contact PD/PI: Tran, Tuan Manh

OMB Number: 4040-0001

Expiration Date: 06/30/2016

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date:

2016-07-12T10:54:42.000-04:00

RESEARCH & RELATED Senior/Key Person Profile (Expanded)

PROFILE - Project Director/Principal Investigator

Prefix: Dr. First Name*: Tuan Middle Name Manh Last Name*: Tran Suffix: 

Position/Title*: Assistant Professor of Medicine

Organization Name*: Indiana Unviversity

Department:

Division:

Street1*:

Street2:

City*:

County:

State*:

Province:

Country*:

Zip / Postal Code*:

Phone Number*:  Fax Number:  E-Mail*: 

Credential, e.g., agency login: 

Project Role*:  PD/PI Other Project Role Category: 

Degree Type:  MD, PHD, BS Degree Year:  2007/2005/1999

File Name Mime Type

Attach Biographical Sketch*: biosketch-Tran.Tuan_070716.pdf application/pdf

Attach Current & Pending Support:

 Page 18
Contact PD/PI: Tran, Tuan Manh

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date:

2016-07-12T10:54:42.000-04:00

PROFILE - Senior/Key Person

Prefix: Dr. First Name*: Chandy Middle Name C. Last Name*: John Suffix: 

Position/Title*: Professor, Pediatrics, Micro & Immunology

Organization Name*: Indiana University

Department: Medicine

Division: Pediatrics, Microbiology/Immun

Street1*:

Street2:

City*:

County:

State*:

Province:

Country*:

Zip / Postal Code*:

Phone Number*:  Fax Number:  E-Mail*: 

Credential, e.g., agency login: 

Project Role*:  Other (Specify) Other Project Role Category: Mentor

Degree Type:  MD, MS Degree Year:  1988/2001

File Name Mime Type

Attach Biographical Sketch*: John_Bios.pdf application/pdf

Attach Current & Pending Support:

PROFILE - Senior/Key Person

Prefix: Dr. First Name*: Wanzhu Middle Name  Last Name*: Tu Suffix: Ph.D

Position/Title*: Professor

Organization Name*: Indiana University

Department: School of Medicine

Division: Biostatistics

Street1*: Wanzhu Tu, PHD

Street2: Dept. of Biostatistics

City*: Indianapolis

County: Marion

State*: IN: Indiana

Province:

Country*: USA: UNITED STATES

Zip / Postal Code*: 462023012

Phone Number*:  Fax Number:  E-Mail*: 

Credential, e.g., agency login: 

Project Role*:  Other (Specify) Other Project Role Category: Co-Mentor

Degree Type:  PHD Degree Year:  1997

File Name Mime Type

Attach Biographical Sketch*: Bios_TU_070716.pdf application/pdf

Attach Current & Pending Support:

 Page 19
Contact PD/PI: Tran, Tuan Manh

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date:

2016-07-12T10:54:42.000-04:00

PROFILE - Senior/Key Person

Prefix: Dr. First Name*: Peter Middle Name D. Last Name*: Crompton Suffix: 

Position/Title*: Chief

Organization Name*: National Institute of Allergy and Infectious Diseases

Department: Intramural research

Division: Lymphocyte Activation Section

Street1*:

Street2:

City*:

County:

State*:

Province:

Country*:

Zip / Postal Code*:

Phone Number*:  Fax Number:  E-Mail*: 

Credential, e.g., agency login: 

Project Role*:  Other (Specify) Other Project Role Category: Co-mentor

Degree Type:  MD Degree Year:  2000

File Name Mime Type

Attach Biographical Sketch*: CromptonBio_070116.pdf application/pdf

Attach Current & Pending Support:

PROFILE - Senior/Key Person

Prefix: Dr. First Name*: Lang Middle Name  Last Name*: Li Suffix: 

Position/Title*: Professor

Organization Name*: Indiana University

Department: Medicine

Division: Bioinformatics

Street1*: Indiana University

Street2: DEPT of MEDICINE, DIV of BIOSTAT

City*: Indianapolis

County: Marion

State*: IN: Indiana

Province:

Country*: USA: UNITED STATES

Zip / Postal Code*: 462023012

Phone Number*:  Fax Number:  E-Mail*: 

Credential, e.g., agency login: 

Project Role*:  Other (Specify) Other Project Role Category: Co-mentor

Degree Type:  PHD, MA, BA Degree Year:  2001/1996/1992

File Name Mime Type

Attach Biographical Sketch*: LangLiBiosketch.pdf application/pdf

Attach Current & Pending Support:

 Page 20
Contact PD/PI: Tran, Tuan Manh

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date:

2016-07-12T10:54:42.000-04:00

PROFILE - Senior/Key Person

Prefix: Dr. First Name*: Sangeeta Middle Name N. Last Name*: Bhatia Suffix: 

Position/Title*: Professor

Organization Name*: Massachusetts Institute of Technology

Department: IMES

Division: Molecular Biology

Street1*: MIT-Institute for Medical Engineering & Science

Street2:

City*:

County:

State*:

Province:

Country*:

Zip / Postal Code*:

Phone Number*:  Fax Number:  E-Mail*: 

Credential, e.g., agency login: 

Project Role*:  Other (Specify) Other Project Role Category: Collaborator

Degree Type:  MD, PHD Degree Year:  1999/1997

File Name Mime Type

Attach Biographical Sketch*: SangeetaBhatiaBiosketch.pdf application/pdf

Attach Current & Pending Support:

PROFILE - Senior/Key Person

Prefix: Dr. First Name*: Philip Middle Name Louis Last Name*: Felgner Suffix: 

Position/Title*: Adjunct Professor

Organization Name*: University of California

Department: Medicine

Division: Infectious Disease

Street1*: Division of Infectious Disease

Street2: Department of Medicine

City*: Irvine

County:

State*: CA: California

Province:

Country*: USA: UNITED STATES

Zip / Postal Code*: 92869-0000

Phone Number*:  Fax Number:  E-Mail*: 

Credential, e.g., agency login: pfelgner

Project Role*:  Other (Specify) Other Project Role Category: Collaborator

Degree Type:  PHD,MS,BS Degree Year:  1978/4975/1972

File Name Mime Type

Attach Biographical Sketch*: PhillipFelgnerBiosketch.pdf application/pdf

Attach Current & Pending Support:

 Page 21
Contact PD/PI: Tran, Tuan Manh

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date:

2016-07-12T10:54:42.000-04:00

PROFILE - Senior/Key Person

Prefix: Dr. First Name*: Scott Middle Name D. Last Name*: Michaels Suffix: 

Position/Title*: Professor

Organization Name*: Indiana University

Department: Medicine

Division: Biology

Street1*:

Street2:

City*:

County:

State*:

Province:

Country*:

Zip / Postal Code*:

Phone Number*:  Fax Number:  E-Mail*: 

Credential, e.g., agency login: 

Project Role*:  Other (Specify) Other Project Role Category: Collaborator

Degree Type:  PHD,BS Degree Year: 

File Name Mime Type

Attach Biographical Sketch*: MichaelsBiosketch.pdf application/pdf

Attach Current & Pending Support:

PROFILE - Senior/Key Person

Prefix: Dr. First Name*: Kara Middle Name Kay Last Name*: Wools-Kaloustian Suffix: 

Position/Title*: Associate Professor

Organization Name*: Indiana University

Department: Medicine

Division: Infectious Diseases

Street1*:

Street2:

City*:

County:

State*:

Province:

Country*:

Zip / Postal Code*:

Phone Number*:  Fax Number:  E-Mail*: 

Credential, e.g., agency login: 

Project Role*:  Other (Specify) Other Project Role Category: Collaborator

Degree Type:  MD, BA Degree Year:  1988/1984

File Name Mime Type

Attach Biographical Sketch*: Kara_WoolsKaloustian_Biosketch_Tuan_K08.pdf

application/pdf

Attach Current & Pending Support:

 Page 22
 

•
Contact PD/PI: Tran, Tuan Manh

 

 

Biosketches Page 24
Contact PD/PI: Tran, Tuan Manh

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Biosketches Page 25
Contact PD/PI: Tran, Tuan Manh

 

Biosketches Page 26
 

 

 

 

 

 

 
 
 
Contact PD/PI: Tran, Tuan Manh

Biosketches Page 30
Contact PD/PI: Tran, Tuan Manh

 

 

 

 

 

 

 

. 

Biosketches Page 31
Contact PD/PI: Tran, Tuan Manh

 

 

 

 

 

 Page 32
Contact PD/PI: Tran, Tuan Manh

 

 

Biosketches Page 33
Contact PD/PI: Tran, Tuan Manh

 

Biosketches Page 34
 

 

 
Contact PD/PI: Tran, Tuan Manh

 

 

 

 

 

 

Tu 

 

Biosketches Page 36
 

 
Contact PD/PI: Tran, Tuan Manh

Infectious Disease. 57(1):40-7; 2013.

Biosketches Page 38
Contact PD/PI: Tran, Tuan Manh

 
Contact PD/PI: Tran, Tuan Manh

 

 Page 40
Contact PD/PI: Tran, Tuan Manh

Biosketches Page 41
 

 

 

 

 

 

 

 

 

 

 

 

 
 
 

 

 

 

 

 

 

 

 
Contact PD/PI: Tran, Tuan Manh

 

 

 

 

 

 

 

 

 

 Page 45
Contact PD/PI: Tran, Tuan Manh

 

 

 

 

 Page 46
Contact PD/PI: Tran, Tuan Manh

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Biosketches Page 47
Contact PD/PI: Tran, Tuan Manh

Biosketches Page 48
 

 

 
Contact PD/PI: Tran, Tuan Manh

 

 

 

 

 

 

 

 

 

 

 Page 50
 
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
 

 

 

 

 

 

 

 
 

•

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
Contact PD/PI: Tran, Tuan Manh

 

 

 

 

 

 

 

 

 Page 55
 

 

 

 

 

 

 

 

 

 

 

 
 

 

 

 

 

 

 

 

 

 

 

 

 

. Plant Cell and 
 

 
Contact PD/PI: Tran, Tuan Manh

 

 

Biosketches Page 59
 

 

 

 

 

 
Contact PD/PI: Tran, Tuan Manh

 

 

Biosketches Page 61
Contact PD/PI: Tran, Tuan Manh

 

 

 

 

 

the

 Page 62
Contact PD/PI: Tran, Tuan Manh

 

 

 

 

 Page 63
OMB Number: 4040-0001

Expiration Date: 06/30/2016

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date: 2016-07-12T10:54:42.000-04:00

RESEARCH & RELATED BUDGET - SECTION A & B, Budget Period  1

ORGANIZATIONAL DUNS*:   

Budget Type*: ● Project ❍ Subaward/Consortium

Enter name of Organization: The Trustees of Indiana University

Start Date*: 04-01-2017 End Date*: 06-30-2018 Budget Period: 1

A. Senior/Key Person

# Prefix First Name* Middle

Name

Last Name* Suffix Project Role* Base

Salary ($)

Calendar

Months

Academic

Months

Summer

Months

Requested

Salary ($)*

Fringe

Benefits ($)*

Funds Requested ($)*

1 . Dr. Tuan Manh Tran PD/PI 9.0

2 . Dr. Tuan Manh Tran PD/PI (IUHP) 9.0

Total Funds Requested for all Senior Key Persons in the attached file

Additional Senior Key Persons: File Name: Total Senior/Key Person

Mime Type:

B. Other Personnel

Number of

Personnel*

Project Role* Calendar Months Academic Months Summer Months Requested Salary ($)* Fringe Benefits* Funds Requested ($)*

Post Doctoral Associates

Graduate Students

Undergraduate Students

Secretarial/Clerical

0 Total Number Other Personnel Total Other Personnel 0.00

Total Salary, Wages and Fringe Benefits (A+B)

RESEARCH & RELATED Budget {A-B} (Funds Requested)

Contact PD/PI: Tran, Tuan Manh

 Page 64
Contact PD/PI: Tran, Tuan Manh

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date:

2016-07-12T10:54:42.000-04:00

RESEARCH & RELATED BUDGET - SECTION C, D, & E, Budget Period 1

ORGANIZATIONAL DUNS*: 

Budget Type*: ● Project ❍ Subaward/Consortium

Organization: The Trustees of Indiana University

Start Date*: 04-01-2017 End Date*: 06-30-2018 Budget Period: 1

C. Equipment Description

List items and dollar amount for each item exceeding $5,000

Equipment Item Funds Requested ($)*

Total funds requested for all equipment listed in the attached file

Total Equipment 0.00

Additional Equipment: File Name:

Mime Type:

D. Travel Funds Requested ($)*

1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions) 0.00

2. Foreign Travel Costs

Total Travel Cost 0.00

E. Participant/Trainee Support Costs Funds Requested ($)*

1. Tuition/Fees/Health Insurance

2. Stipends

3. Travel

4. Subsistence

5. Other: 

 Number of Participants/Trainees Total Participant Trainee Support Costs 0.00

RESEARCH & RELATED Budget {C-E} (Funds Requested)

 Page 65
Contact PD/PI: Tran, Tuan Manh

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date:

2016-07-12T10:54:42.000-04:00

RESEARCH & RELATED BUDGET - SECTIONS F-K, Budget Period 1

ORGANIZATIONAL DUNS*: 

Budget Type*: ● Project ❍ Subaward/Consortium

Organization: The Trustees of Indiana University

Start Date*: 04-01-2017 End Date*: 06-30-2018 Budget Period: 1

F. Other Direct Costs Funds Requested ($)*

1. Materials and Supplies

2. Publication Costs

3. Consultant Services

4. ADP/Computer Services

5. Subawards/Consortium/Contractual Costs

6. Equipment or Facility Rental/User Fees

7. Alterations and Renovations

Total Other Direct Costs

G. Direct Costs Funds Requested ($)*

Total Direct Costs (A thru F)

H. Indirect Costs

Indirect Cost Type Indirect Cost Rate (%) Indirect Cost Base ($) Funds Requested ($)*

1 . MTDC 8.0

Total Indirect Costs

Cognizant Federal Agency

(Agency Name, POC Name, and POC Phone Number)

Department of Health and Human Services (D.H.H.S.) Arif Karim,

(214) 767-3261

I. Total Direct and Indirect Costs Funds Requested ($)*

Total Direct and Indirect Institutional Costs (G + H)

J. Fee Funds Requested ($)*

K. Budget Justification* File Name: K08_BudgetJustification_070516revised.pdfMime Type: application/pdf

(Only attach one file.)

RESEARCH & RELATED Budget {F-K} (Funds Requested)

 Page 66
OMB Number: 4040-0001

Expiration Date: 06/30/2016

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date: 2016-07-12T10:54:42.000-04:00

RESEARCH & RELATED BUDGET - SECTION A & B, Budget Period  2

ORGANIZATIONAL DUNS*:   

Budget Type*: ● Project ❍ Subaward/Consortium

Enter name of Organization: The Trustees of Indiana University

Start Date*: 04-01-2018 End Date*: 03-31-2019 Budget Period: 2

A. Senior/Key Person

# Prefix First Name* Middle

Name

Last Name* Suffix Project Role* Base

Salary ($)

Calendar

Months

Academic

Months

Summer

Months

Requested

Salary ($)*

Fringe

Benefits ($)*

Funds Requested ($)*

1 . Dr. Tuan Manh Tran PD/PI 9.0

2 . Dr. Tuan Manh Tran PD/PI (IUHP) 9.0

Total Funds Requested for all Senior Key Persons in the attached file

Additional Senior Key Persons: File Name: Total Senior/Key Person

Mime Type:

B. Other Personnel

Number of

Personnel*

Project Role* Calendar Months Academic Months Summer Months Requested Salary ($)* Fringe Benefits* Funds Requested ($)*

Post Doctoral Associates

Graduate Students

Undergraduate Students

Secretarial/Clerical

0 Total Number Other Personnel Total Other Personnel 0.00

Total Salary, Wages and Fringe Benefits (A+B)

RESEARCH & RELATED Budget {A-B} (Funds Requested)

Contact PD/PI: Tran, Tuan Manh

 Page 67
Contact PD/PI: Tran, Tuan Manh

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date:

2016-07-12T10:54:42.000-04:00

RESEARCH & RELATED BUDGET - SECTION C, D, & E, Budget Period 2

ORGANIZATIONAL DUNS*: 

Budget Type*: ● Project ❍ Subaward/Consortium

Organization: The Trustees of Indiana University

Start Date*: 04-01-2018 End Date*: 03-31-2019 Budget Period: 2

C. Equipment Description

List items and dollar amount for each item exceeding $5,000

Equipment Item Funds Requested ($)*

Total funds requested for all equipment listed in the attached file

Total Equipment 0.00

Additional Equipment: File Name:

Mime Type:

D. Travel Funds Requested ($)*

1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions) 0.00

2. Foreign Travel Costs

Total Travel Cost 0.00

E. Participant/Trainee Support Costs Funds Requested ($)*

1. Tuition/Fees/Health Insurance

2. Stipends

3. Travel

4. Subsistence

5. Other: 

 Number of Participants/Trainees Total Participant Trainee Support Costs 0.00

RESEARCH & RELATED Budget {C-E} (Funds Requested)

 Page 68
Contact PD/PI: Tran, Tuan Manh

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date:

2016-07-12T10:54:42.000-04:00

RESEARCH & RELATED BUDGET - SECTIONS F-K, Budget Period 2

ORGANIZATIONAL DUNS*: 

Budget Type*: ● Project ❍ Subaward/Consortium

Organization: The Trustees of Indiana University

Start Date*: 04-01-2018 End Date*: 03-31-2019 Budget Period: 2

F. Other Direct Costs Funds Requested ($)*

1. Materials and Supplies

2. Publication Costs

3. Consultant Services

4. ADP/Computer Services

5. Subawards/Consortium/Contractual Costs

6. Equipment or Facility Rental/User Fees

7. Alterations and Renovations

Total Other Direct Costs

G. Direct Costs Funds Requested ($)*

Total Direct Costs (A thru F)

H. Indirect Costs

Indirect Cost Type Indirect Cost Rate (%) Indirect Cost Base ($) Funds Requested ($)*

1 . MTDC 8.0

Total Indirect Costs

Cognizant Federal Agency

(Agency Name, POC Name, and POC Phone Number)

Department of Health and Human Services (D.H.H.S.) Arif Karim,

(214) 767-3261

I. Total Direct and Indirect Costs Funds Requested ($)*

Total Direct and Indirect Institutional Costs (G + H)

J. Fee Funds Requested ($)*

K. Budget Justification* File Name: K08_BudgetJustification_070516revised.pdfMime Type: application/pdf

(Only attach one file.)

RESEARCH & RELATED Budget {F-K} (Funds Requested)

 Page 69
OMB Number: 4040-0001

Expiration Date: 06/30/2016

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date: 2016-07-12T10:54:42.000-04:00

RESEARCH & RELATED BUDGET - SECTION A & B, Budget Period  3

ORGANIZATIONAL DUNS*:   

Budget Type*: ● Project ❍ Subaward/Consortium

Enter name of Organization: The Trustees of Indiana University

Start Date*: 04-01-2019 End Date*: 03-31-2020 Budget Period: 3

A. Senior/Key Person

# Prefix First Name* Middle

Name

Last Name* Suffix Project Role* Base

Salary ($)

Calendar

Months

Academic

Months

Summer

Months

Requested

Salary ($)*

Fringe

Benefits ($)*

Funds Requested ($)*

1 . Dr. Tuan Manh Tran PD/PI 9.0

2 . Dr. Tuan Manh Tran PD/PI (IUHP) 9.0

Total Funds Requested for all Senior Key Persons in the attached file

Additional Senior Key Persons: File Name: Total Senior/Key Person

Mime Type:

B. Other Personnel

Number of

Personnel*

Project Role* Calendar Months Academic Months Summer Months Requested Salary ($)* Fringe Benefits* Funds Requested ($)*

Post Doctoral Associates

Graduate Students

Undergraduate Students

Secretarial/Clerical

0 Total Number Other Personnel Total Other Personnel 0.00

Total Salary, Wages and Fringe Benefits (A+B)

RESEARCH & RELATED Budget {A-B} (Funds Requested)

Contact PD/PI: Tran, Tuan Manh

 Page 70
Contact PD/PI: Tran, Tuan Manh

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date:

2016-07-12T10:54:42.000-04:00

RESEARCH & RELATED BUDGET - SECTION C, D, & E, Budget Period 3

ORGANIZATIONAL DUNS*: 

Budget Type*: ● Project ❍ Subaward/Consortium

Organization: The Trustees of Indiana University

Start Date*: 04-01-2019 End Date*: 03-31-2020 Budget Period: 3

C. Equipment Description

List items and dollar amount for each item exceeding $5,000

Equipment Item Funds Requested ($)*

Total funds requested for all equipment listed in the attached file

Total Equipment 0.00

Additional Equipment: File Name:

Mime Type:

D. Travel Funds Requested ($)*

1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions) 0.00

2. Foreign Travel Costs

Total Travel Cost 0.00

E. Participant/Trainee Support Costs Funds Requested ($)*

1. Tuition/Fees/Health Insurance

2. Stipends

3. Travel

4. Subsistence

5. Other: 

 Number of Participants/Trainees Total Participant Trainee Support Costs 0.00

RESEARCH & RELATED Budget {C-E} (Funds Requested)

 Page 71
Contact PD/PI: Tran, Tuan Manh

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date:

2016-07-12T10:54:42.000-04:00

RESEARCH & RELATED BUDGET - SECTIONS F-K, Budget Period 3

ORGANIZATIONAL DUNS*: 

Budget Type*: ● Project ❍ Subaward/Consortium

Organization: The Trustees of Indiana University

Start Date*: 04-01-2019 End Date*: 03-31-2020 Budget Period: 3

F. Other Direct Costs Funds Requested ($)*

1. Materials and Supplies

2. Publication Costs

3. Consultant Services

4. ADP/Computer Services

5. Subawards/Consortium/Contractual Costs

6. Equipment or Facility Rental/User Fees

7. Alterations and Renovations

Total Other Direct Costs

G. Direct Costs Funds Requested ($)*

Total Direct Costs (A thru F)

H. Indirect Costs

Indirect Cost Type Indirect Cost Rate (%) Indirect Cost Base ($) Funds Requested ($)*

1 . MTDC 8.0

Total Indirect Costs

Cognizant Federal Agency

(Agency Name, POC Name, and POC Phone Number)

Department of Health and Human Services (D.H.H.S.) Arif Karim,

(214) 767-3261

I. Total Direct and Indirect Costs Funds Requested ($)*

Total Direct and Indirect Institutional Costs (G + H)

J. Fee Funds Requested ($)*

K. Budget Justification* File Name: K08_BudgetJustification_070516revised.pdfMime Type: application/pdf

(Only attach one file.)

RESEARCH & RELATED Budget {F-K} (Funds Requested)

 Page 72
OMB Number: 4040-0001

Expiration Date: 06/30/2016

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date: 2016-07-12T10:54:42.000-04:00

RESEARCH & RELATED BUDGET - SECTION A & B, Budget Period  4

ORGANIZATIONAL DUNS*:   

Budget Type*: ● Project ❍ Subaward/Consortium

Enter name of Organization: The Trustees of Indiana University

Start Date*: 04-01-2020 End Date*: 03-31-2021 Budget Period: 4

A. Senior/Key Person

# Prefix First Name* Middle

Name

Last Name* Suffix Project Role* Base

Salary ($)

Calendar

Months

Academic

Months

Summer

Months

Requested

Salary ($)*

Fringe

Benefits ($)*

Funds Requested ($)*

1 . Dr. Tuan Manh Tran PD/PI 9.0

2 . Dr. Tuan Manh Tran PD/PI (IUHP) 9.0

Total Funds Requested for all Senior Key Persons in the attached file

Additional Senior Key Persons: File Name: Total Senior/Key Person

Mime Type:

B. Other Personnel

Number of

Personnel*

Project Role* Calendar Months Academic Months Summer Months Requested Salary ($)* Fringe Benefits* Funds Requested ($)*

Post Doctoral Associates

Graduate Students

Undergraduate Students

Secretarial/Clerical

0 Total Number Other Personnel Total Other Personnel 0.00

Total Salary, Wages and Fringe Benefits (A+B)

RESEARCH & RELATED Budget {A-B} (Funds Requested)

Contact PD/PI: Tran, Tuan Manh

 Page 73
Contact PD/PI: Tran, Tuan Manh

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date:

2016-07-12T10:54:42.000-04:00

RESEARCH & RELATED BUDGET - SECTION C, D, & E, Budget Period 4

ORGANIZATIONAL DUNS*: 

Budget Type*: ● Project ❍ Subaward/Consortium

Organization: The Trustees of Indiana University

Start Date*: 04-01-2020 End Date*: 03-31-2021 Budget Period: 4

C. Equipment Description

List items and dollar amount for each item exceeding $5,000

Equipment Item Funds Requested ($)*

Total funds requested for all equipment listed in the attached file

Total Equipment 0.00

Additional Equipment: File Name:

Mime Type:

D. Travel Funds Requested ($)*

1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions) 0.00

2. Foreign Travel Costs

Total Travel Cost 0.00

E. Participant/Trainee Support Costs Funds Requested ($)*

1. Tuition/Fees/Health Insurance

2. Stipends

3. Travel

4. Subsistence

5. Other: 

 Number of Participants/Trainees Total Participant Trainee Support Costs 0.00

RESEARCH & RELATED Budget {C-E} (Funds Requested)

 Page 74
Contact PD/PI: Tran, Tuan Manh

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date:

2016-07-12T10:54:42.000-04:00

RESEARCH & RELATED BUDGET - SECTIONS F-K, Budget Period 4

ORGANIZATIONAL DUNS*: 

Budget Type*: ● Project ❍ Subaward/Consortium

Organization: The Trustees of Indiana University

Start Date*: 04-01-2020 End Date*: 03-31-2021 Budget Period: 4

F. Other Direct Costs Funds Requested ($)*

1. Materials and Supplies

2. Publication Costs

3. Consultant Services

4. ADP/Computer Services

5. Subawards/Consortium/Contractual Costs

6. Equipment or Facility Rental/User Fees

7. Alterations and Renovations

Total Other Direct Costs

G. Direct Costs Funds Requested ($)*

Total Direct Costs (A thru F)

H. Indirect Costs

Indirect Cost Type Indirect Cost Rate (%) Indirect Cost Base ($) Funds Requested ($)*

1 . MTDC 8.0

Total Indirect Costs

Cognizant Federal Agency

(Agency Name, POC Name, and POC Phone Number)

Department of Health and Human Services (D.H.H.S) Arif Karim

(214) 767-3261

I. Total Direct and Indirect Costs Funds Requested ($)*

Total Direct and Indirect Institutional Costs (G + H)

J. Fee Funds Requested ($)*

K. Budget Justification* File Name: K08_BudgetJustification_070516revised.pdfMime Type: application/pdf

(Only attach one file.)

RESEARCH & RELATED Budget {F-K} (Funds Requested)

 Page 75
OMB Number: 4040-0001

Expiration Date: 06/30/2016

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date: 2016-07-12T10:54:42.000-04:00

RESEARCH & RELATED BUDGET - SECTION A & B, Budget Period  5

ORGANIZATIONAL DUNS*:   

Budget Type*: ● Project ❍ Subaward/Consortium

Enter name of Organization: The Trustees of Indiana University

Start Date*: 04-01-2021 End Date*: 03-31-2022 Budget Period: 5

A. Senior/Key Person

# Prefix First Name* Middle

Name

Last Name* Suffix Project Role* Base

Salary ($)

Calendar

Months

Academic

Months

Summer

Months

Requested

Salary ($)*

Fringe

Benefits ($)*

Funds Requested ($)*

1 . Dr. Tuan Manh Tran PD/PI 9.0

2 . Dr. Tuan Manh Tran PD/PI (IUHP) 9.0

Total Funds Requested for all Senior Key Persons in the attached file

Additional Senior Key Persons: File Name: Total Senior/Key Person

Mime Type:

B. Other Personnel

Number of

Personnel*

Project Role* Calendar Months Academic Months Summer Months Requested Salary ($)* Fringe Benefits* Funds Requested ($)*

Post Doctoral Associates

Graduate Students

Undergraduate Students

Secretarial/Clerical

0 Total Number Other Personnel Total Other Personnel 0.00

Total Salary, Wages and Fringe Benefits (A+B)

RESEARCH & RELATED Budget {A-B} (Funds Requested)

Contact PD/PI: Tran, Tuan Manh

 Page 76
Contact PD/PI: Tran, Tuan Manh

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date:

2016-07-12T10:54:42.000-04:00

RESEARCH & RELATED BUDGET - SECTION C, D, & E, Budget Period 5

ORGANIZATIONAL DUNS*: 

Budget Type*: ● Project ❍ Subaward/Consortium

Organization: The Trustees of Indiana University

Start Date*: 04-01-2021 End Date*: 03-31-2022 Budget Period: 5

C. Equipment Description

List items and dollar amount for each item exceeding $5,000

Equipment Item Funds Requested ($)*

Total funds requested for all equipment listed in the attached file

Total Equipment 0.00

Additional Equipment: File Name:

Mime Type:

D. Travel Funds Requested ($)*

1. Domestic Travel Costs ( Incl. Canada, Mexico, and U.S. Possessions) 0.00

2. Foreign Travel Costs

Total Travel Cost 0.00

E. Participant/Trainee Support Costs Funds Requested ($)*

1. Tuition/Fees/Health Insurance

2. Stipends

3. Travel

4. Subsistence

5. Other: 

 Number of Participants/Trainees Total Participant Trainee Support Costs 0.00

RESEARCH & RELATED Budget {C-E} (Funds Requested)

 Page 77
Contact PD/PI: Tran, Tuan Manh

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date:

2016-07-12T10:54:42.000-04:00

RESEARCH & RELATED BUDGET - SECTIONS F-K, Budget Period 5

ORGANIZATIONAL DUNS*: 

Budget Type*: ● Project ❍ Subaward/Consortium

Organization: The Trustees of Indiana University

Start Date*: 04-01-2021 End Date*: 03-31-2022 Budget Period: 5

F. Other Direct Costs Funds Requested ($)*

1. Materials and Supplies

2. Publication Costs

3. Consultant Services

4. ADP/Computer Services

5. Subawards/Consortium/Contractual Costs

6. Equipment or Facility Rental/User Fees

7. Alterations and Renovations

Total Other Direct Costs

G. Direct Costs Funds Requested ($)*

Total Direct Costs (A thru F)

H. Indirect Costs

Indirect Cost Type Indirect Cost Rate (%) Indirect Cost Base ($) Funds Requested ($)*

1 . MTDC 8.0

Total Indirect Costs

Cognizant Federal Agency

(Agency Name, POC Name, and POC Phone Number)

Department of Health and Human Services (D.H.H.S.) Arif Karim,

(214) 767-3261

I. Total Direct and Indirect Costs Funds Requested ($)*

Total Direct and Indirect Institutional Costs (G + H)

J. Fee Funds Requested ($)*

K. Budget Justification* File Name: K08_BudgetJustification_070516revised.pdfMime Type: application/pdf

(Only attach one file.)

RESEARCH & RELATED Budget {F-K} (Funds Requested)

 Page 78
Contact PD/PI: Tran, Tuan Manh

Budget Justification:

Tuan Tran, M.D., PhD, Principal Investigator (9.00 calendar months): Dr. Tran is an Assistant Professor of 

Medicine in the Division of Infectious Diseases at Indiana University School of Medicine. His appointment began

on Sept 1, 2015. Dr. Tran will conduct all work associated with this study as proposed and will interpret data. 

Indiana University Health Physicians

Dr. Tran receives compensation from two sources as a faculty member with the Department of Medicine. The 

first source is from Indiana University (IU). The second source is from a third-party, non-profit corporation, Indiana 

University Health Physicians (IUHP), whose mission is to support the instruction, research and public service 

missions of the IU School of Medicine. It is certified the two sources of income comprise a single compensation 

package for Dr. Tran, which complies with the NIH guidelines on institutional-based salary (NIH Notice NOT-OD05-061). Dr. Tran will devote 9.00 calendar months to the project; accordingly, the two sets of calendar month 

figures shown in the budget should not be added together to establish effort – the second figure is repeated to 

reflect the correct split between two sources for one institutional-based salary. 

 

 Materials and Supplies: $ yr.1; $ yr.2; $ yr.3; $ yr.4; and $ yr.5

 

RNA Extraction 

RNA-Seq Library Preparation and Sequencing 

Consumable plasticware 

DNA extraction 

PCR reagents 

One meeting to present data 

Shipping 

RNA-seq Mapping Services 

4 TB External Hard Drives 

Protein Array Materials and Service 

Budget Justification Attachment Page 79
Contact PD/PI: Tran, Tuan Manh

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date:

2016-07-12T10:54:42.000-04:00

RESEARCH & RELATED BUDGET - Cumulative Budget

Totals ($)

Section A, Senior/Key Person

Section B, Other Personnel 0.00

Total Number Other Personnel 0

Total Salary, Wages and Fringe Benefits

(A+B)

Section C, Equipment 0.00

Section D, Travel 0.00

1. Domestic 0.00

2. Foreign 0.00

Section E, Participant/Trainee Support

Costs

0.00

1. Tuition/Fees/Health Insurance 0.00

2. Stipends 0.00

3. Travel 0.00

4. Subsistence 0.00

5. Other 0.00

6. Number of Participants/Trainees 0

Section F, Other Direct Costs

1. Materials and Supplies

2. Publication Costs 0.00

3. Consultant Services 0.00

4. ADP/Computer Services 0.00

5. Subawards/Consortium/Contractual

Costs

0.00

6. Equipment or Facility Rental/User

Fees

0.00

7. Alterations and Renovations 0.00

8. Other 1 0.00

9. Other 2 0.00

10. Other 3 0.00

Section G, Direct Costs

(A thru F)

Section H, Indirect Costs

Section I, Total Direct and Indirect Costs

(G + H)

Section J, Fee 0.00

 Page 80
PHS 398 Cover Page Supplement

OMB Number: 0925-0001

Expiration Date: 10/31/2018

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date:

2016-07-12T10:54:42.000-04:00

1. Human Subjects Section

Clinical Trial? ❍ Yes ● No

*Agency-Defined Phase III Clinical Trial? ❍ Yes ❍ No

2. Vertebrate Animals Section

Are vertebrate animals euthanized? ❍ Yes ❍ No

If "Yes" to euthanasia

Is the method consistent with American Veterinary Medical Association (AVMA) guidelines?

❍ Yes ❍ No

If "No" to AVMA guidelines, describe method and proved scientific justification

3. *Program Income Section

*Is program income anticipated during the periods for which the grant support is requested?

❍ Yes ● No

If you checked "yes" above (indicating that program income is anticipated), then use the format below to reflect the amount and

source(s). Otherwise, leave this section blank.

*Budget Period *Anticipated Amount ($) *Source(s)

Contact PD/PI: Tran, Tuan Manh

 Page 81
PHS 398 Cover Page Supplement

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191 . Received Date:

2016-07-12T10:54:42.000-04:00

4. Human Embryonic Stem Cells Section

*Does the proposed project involve human embryonic stem cells? ❍ Yes ● No

If the proposed project involves human embryonic stem cells, list below the registration number of the specific cell line(s) from the

following list: http://grants.nih.gov/stem_cells/registry/current.htm. Or, if a specific stem cell line cannot be referenced at this time,

please check the box indicating that one from the registry will be used:

❏ Specific stem cell line cannot be referenced at this time. One from the registry will be used.

Cell Line(s) (Example: 0004):

5. Inventions and Patents Section (RENEWAL)

*Inventions and Patents: ❍ Yes ❍ No

If the answer is "Yes" then please answer the following:

*Previously Reported: ❍ Yes ❍ No

6. Change of Investigator / Change of Institution Section

❏ Change of Project Director / Principal Investigator

Name of former Project Director / Principal Investigator

Prefix:

*First Name:

Middle Name:

*Last Name:

Suffix:

❏ Change of Grantee Institution

*Name of former institution:

Contact PD/PI: Tran, Tuan Manh

 Page 82
PHS 398 Career Development Award Supplemental Form

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191. Received Date:

2016-07-12T10:54:42.000-04:00

OMB Number: 0925-0001

Expiration Date: 10/31/2018

Introduction

1. Introduction to Application

(RESUBMISSION)

K08_Introduction_07072016.pdf

Candidate Section

2. Candidate Information and Goals for Career

Development

K08_Candidate_Information_07082016.pdf

Research Plan Section

3. Specific Aims K08_Specific_Aims_07062016.pdf

4. Research Strategy* K08_Research_Strategy_07072016.pdf

5. Progress Report Publication List

(for RENEWAL applications only)

6. Training in the Responsible Conduct of Research K08_Training_In_Responsible_Conduct_of_Research.pdf

Other Candidate Information Section

7. Candidate's Plan to Provide Mentoring

Mentor, Co-Mentor, Consultant, Collaborators Section

8. Plans and Statements of Mentor and

Co-Mentor(s)

Mentor_Statements_Chandy_Crompton_Li_Wantzu.pdf

9. Letters of Support from Collaborators,

Contributors, and Consultants

Letters_ofS_support_Bhatia_Boubacar_Wools-Kaloustian_Felgner.pdf

Environment and Institutional Commitment to Candidate Section

10. Description of Institutional Environment K08_Description_of_the_Institutional_Environment__07072016.pdf

11. Institutional Commitment to Candidate's

Research Career Development

TRAN_Institutional_Commitment_Ltr_K08_Geraci_Resubmission.pdf

Human Subject Section

12. Protection of Human Subjects K08_Protection_of_Human_Subjects_01.pdf

13. Data Safety Monitoring Plan

14. Inclusion of Women and Minorities K08__Inclusion_of_Women_and_Minorities_07012016.pdf

15. Inclusion of Children K08_Inclusion_of_Children.pdf

Other Research Plan Section

16. Vertebrate Animals

17. Select Agent Research

19. Consortium/Contractual Arrangements

19. Resource Sharing K08_Data_Resource_Sharing_Plan_07052016.pdf

20. Authentication of Key Biological and/or

Chemical Resources

K08_Authentication_of_Key_Biological_Resources_07122016.pdf

Appendix

21. Appendix

Contact PD/PI: Tran, Tuan Manh

 Page 83
PHS 398 Career Development Award Supplemental Form

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191. Received Date:

2016-07-12T10:54:42.000-04:00

Citizenship*:

U.S. Citizen or Non-Citizen National?* ❏✔ Yes ❏ No

If no, select most appropriate Non-U.S. Citizen option

❏  With a Permanent U.S. Resident Visa

❏  With a Temporary U.S. Visa

❏  Not Residing in the U.S.

If with a temporary U.S. visa who has applied for permanent resident status and expect to hold a permanent resident

visa by the earliest possible start date of the award, also check here: ❏

Contact PD/PI: Tran, Tuan Manh

 Page 84
Introduction to Resubmission

This is a resubmission of the application 1 K08 AI125682-01, which was reviewed on February 29, 2016 

(MID-B Study Section). As a junior investigator, I am grateful for the reviewers’ comments and have made every 

effort to address each of their critiques. I believe the current application better delineates how systems biology 

approaches will be implemented to identify immune parameters predictive of immunity to P. falciparum (Pf) and

broadens the scope of potential findings by incorporating host genetic and epidemiological factors relevant to 

malaria. The reviewers were enthusiastic of my potential as a K08 candidate, citing that my unique skill set, 

consisting of both field-research experience and knowledge of bioinformatics and systems biology, could allow 

me to excel in cutting-edge biomedical -omics fields. The panel highlighted my eminent team of qualified mentors

and my institution’s commitment to my success. They noted that the application addresses important questions 

in the understudied field of malaria systems immunology and has the potential for success given the track record

of my mentors and unique access to a valuable collection of patient samples. However, several weaknesses 

related to the research and career development plans were outlined. To address these criticisms, the current 

proposal provides more robust classifications of clinical and sterile immunity to P. falciparum (Pf) and details the 

computational methods for integrating epidemiological, clinical, genomic, and immunological data in order to 

predict immune classes, while reinforcing statistical training in the didactic regime to enhance my competence 

in modeling approaches. 

The primary concerns expressed by the panel include the lack of detailed methodologies on how the data 

can be integrated and modeled in order to predict immunity to Pf infection. To address this, we describe in the 

current application how we will test the accuracy of regularized regression models and machine learning 

algorithms in predicting the immune classes, focusing on approaches with robust feature selection that can 

accommodate mixed-type, high-dimensional data (3.2.2h). We outline how these approaches allow us to 

integrate clinical and epidemiological data with high-dimensional biological data from multiple assay platforms, 

and can select for groups of highly correlated variables to derive biological insight. The panel also suggested 

combining Aims 1 and 2 given the overlap in methods. We have indeed combined the original Aims into a 

single Aim 1 and have introduced a revised Aim 2 that adds a comparative, multi-platform analysis between

clinical and sterile immunity (as suggested by the panel) and better integrates the proposed functional assays 

with the gene expression, protein array, and flow cytometry data. 

Reviewer 1 expressed concern that we had overlooked malaria protection afforded by host genetics, 

most notably erythrocyte variants. The original application restricted the study to only HbAA individuals to avoid 

confounding due to HbS and HbC. The current proposal also accounts for ABO blood groups, α+-thalassemia, 

and G6PD deficiency and will incorporate these erythrocyte variants in the above models (3.2.2b). 

Reviewers 2 and 3 suggested additional statistical training, with reviewer 3 emphasizing epidemiology. 

Based on reviewers’ suggestions, we reconstructed my proposed educational program to better cover all the 

statistical and epidemiological training that I need, which includes formal courses integrated with directed reading 

and analyses that I perform under the direct supervision of my statistical mentors (Didactic Training). 

Reviewer 3 was concerned with arbitrary cut-offs and statistical inference made from our power analysis. 

We originally chose 2500 parasites/μl as the threshold for defining malaria episodes to strike a balance between 

sensitivity and specificity for diagnosing malaria in a semi-immune population, where children with low-level Pf

infections exhibiting fevers due to other pathogens may be misclassified. However, we recognize the need for 

increased sensitivity and lowered the threshold to 500 parasites/μl. By doing so, we expand the number of 

episodes for all children, allowing for an indeterminate group (children with 3 episodes) that demarcates the 

clinically immune and susceptible groups. To address concerns about power and sample size adequacy, we 

expanded the original analysis by adding simulation-based estimates of effect sizes using our proposed 

statistical methods and sample sizes based on the actual number of existing biological samples. 

Reviewer 4 expressed concern for the lack of an existing mentoring relationship between IU mentors and 

myself and for a potential reduction in productivity during first years of the K08. I am currently involved in 7 

projects (5 using data previously collected by members of our team and 2 involving new data collection). Three

of these include collaborations with new mentors in my current position, and 4 involve collaboration only with my 

mentor from my prior position. Based on our prior experience, we expect these activities to produce 4-6 

publications over the next 2 years. These activities will help maintain my name recognition in the field. 

In summary, we thank the reviewers for their helpful suggestions. Their critiques have provided us with 

better focus and guided our revisions to significantly improve the resubmission. We believe that the better 

characterized immune and susceptible class definitions, more thorough description of computational methods, 

and more rigorous statistical didactic regime in the revised proposal have resulted in more powerful studies that 

should advance malaria systems immunology and help develop my expertise in this understudied field. 

Contact PD/PI: Tran, Tuan Manh

Introduction to Application Page 85
Candidate Information

I have been fascinated with host responses to microbes ever since grade school, when I was 

introduced to Louis Pasteur by way of a children’s biography. This early fascination, nurtured by the support of 

my physician-father, led me towards formal training as a medical scientist. In high school, I was fortunate to 

work with Dr. Jill Verlander at the University of Florida (UF) College of Medicine. I investigated the effects of 

estrogen on the thiazide-sensitive NaCl co-transporter in the distal convoluted tubule. My continued research in 

Dr. Verlander’s laboratory during my undergraduate studies at UF led to second authorship on a publication 

(19). I graduated from UF as the valedictorian and enrolled in the MSTP at Emory University. As a medical 

student, I happened upon a lecture by the late Dr. Robert Desowitz. Malaria, I learned that evening, was a 

disease that affected ~500 million people yearly, yet there was no effective vaccine. I switched my focus to 

malaria and began my studies in Dr. Mary Galinski’s laboratory. 

For my PhD thesis, I evaluated the Plasmodium vivax reticulocyte binding protein-1 (PvRBP1) as a 

vaccine candidate. I was awarded the Ben H. Kean Fellowship to work in the Brazilian Amazon, where Dr. 

Galinski and FIOCRUZ collaborator Dr. Joseli Oliveira-Ferreira were investigating naturally acquired immune 

responses to P. vivax vaccine candidate antigens. In Brazil, I performed field research and field-based 

immunological assays (20-22). I expressed recombinant fragments spanning the PvRBP1 ectodomain to map

its binding domain (23) and to determine dominant B-cell epitopes (24). I also evaluated the genetic diversity of 

reticulocyte-binding homologues (25). My thesis work resulted in 3 first-author publications (23-25) and showed 

evidence that the N-terminal region of PvRBP1 would be a rationale P. vivax vaccine target (22). After 

graduating from Emory, I completed an Internal Medicine residency at the Johns Hopkins Hospital. As a 

resident, I was the PI on a Johns Hopkins Global Health Grant, which allowed me to independently study 

antigen-specific basophil responses during P. falciparum (Pf) infection in malaria-exposed Malians. 

I completed the first clinical year in the Infectious Diseases Fellowship at NIAID before joining Dr. 

Susan Pierce’s Laboratory of Immunogenetics (LIG), where I began the research phase of my fellowship under 

the supervision of Dr. Peter Crompton. Dr. Crompton’s laboratory collaborates with Dr. Boubacar Traore at the 

Malaria Research and Training Center (MRTC) within the Mali International Center for Excellence in Research 

to study malaria immunity in individuals living in malaria-endemic areas. I helped establish a longitudinal cohort 

study in Kalifabougou, Mali to investigate the molecular and cellular differences between prospectively defined 

malaria-susceptible and immune individuals using systems biology approaches (8). I characterized the cohort 

to define clinically immune and susceptible individuals, which involved retrospectively identifying when 

individuals became infected with Pf and whether or not they progressed to malarial fever. The first year of this 

cohort study yielded much insight into naturally acquired malaria immunity. First, I provided evidence that, 

despite the natural acquisition of clinical immunity to malaria, most individuals in hyperendemic areas did not 

acquire sterile immunity despite years of malaria exposure (7). Second, I showed that naturally acquired IgG to 

Pf reticulocyte binding homologue 5 correlated with reduced malaria risk and inhibited parasite growth in vitro 

(17). Thorough parasitological characterization of the cohort allowed me to elucidate the relationship between 

Schistosoma haematobium infection and malaria risk (18). My analysis of the clinical cohort data and 

computational abilities allowed me to make contributions to other projects, leading to co-authorship on several 

publications (26-32). Since characterizing the initial clinical data, I have focused on determining the differences 

in whole-blood transcriptomes between malaria-immune and susceptible children using RNA-seq (33). 

In September 2015, I joined the Division of Infectious Diseases within the Department of Medicine at 

the Indiana University School of Medicine (IUSM) as a tenure-track Assistant Professor. I chose IUSM due to 

the collaborative atmosphere and the commitment to global health research in the Division led by Dr. Kara 

Wools-Kaloustian. I was drawn to the opportunity for growth in malaria research due to the arrival of Dr. 

Chandy John, who has expertise in malaria immuno-epidemiology and severe human malaria pathogenesis. 

The IUSM Department of Medicine granted me a generous three-year start-up package that includes funding 

for equipment and a technician, independent lab and office space, and 80% protected research time to 

facilitate my development as an independent scientist and establish an extramurally funded translational 

research program focused on malaria immunity. Recently I have been awarded internally funded Indiana-CTSI 

Young Investigator and IU Global Health-Indiana CTSI grants, the latter to start field studies in Western Kenya 

with my mentor Chandy John. My clinical duties include an infectious diseases clinic twice per month and 6 

weeks per year of service as the infectious diseases consult attending. 

Candidate’s Goals For Career Development

I am interested in unraveling the complexities of host immune responses to Plasmodium infection in the 

endemic setting, where children are exposed to a myriad of commensal and pathogenic organisms, since I 

Contact PD/PI: Tran, Tuan Manh

Candidate Information and Goals for Career Development Page 86
believe this is essential to understanding acquired immunity to the parasite and why vaccines that perform well 

in naïve donors have performed poorly in the field (34-36). In field settings, variables related to the host, 

parasite, vector, and environment can influence host responses to infection. Such complexity lends itself well 

to “systems-based” analysis, which requires advanced mathematical and computational approaches to 

determine if and how these parameters interact to influence the host response to the parasite. However, there 

is a dearth of biologists and clinicians who can understand the analysis at the mathematical and computational 

level, necessitating collaboration with computational specialists to help translate the biomedical data into lines 

of code and vice versa (37). As an investigator with training in infectious diseases, immunology, field research, 

and applied bioinformatics, I wish to take the next logical step in my career development and learn the 

advanced statistical and computational approaches required to integrate complex datasets from multiple 

platforms with the purpose of identifying correlates of protection from malaria disease and Pf infection. As 

such, my long-term goal is to acquire expertise in the field of systems biology of malaria, with a particular 

emphasis on modulation of immune responses to Pf by previous exposures/infections, the environment, and 

host factors, and how immunomodulation might influence susceptibility to infection and disease as well as

ineffective vaccine responses. Building upon our previous observations (17, 18, 26, 32), I hope to further 

elucidate the mechanisms by which co-infections and diet influence malaria risk by applying systems biological

methods to well-designed prospective cohort studies. 

My short-term goals, and the focus of this K award proposal, are to determine the immune parameters 

that predict whether a child will be protected from malaria symptoms once parasitemic or protected from Pf

parasitemia outright using systems biology approaches. Differences in immune parameters between children 

who become parasitemic but remain asymptomatic versus those who develop symptoms during parasitemia

could provide insights for “anti-disease” vaccines that mitigate malarial disease but do not prevent Pf infection. 

Identifying differences in immune parameters between children who remain free of P. falciparum parasitemia, 

as documented by bi-weekly, negative PCR’s throughout a 6-month high-transmission season and the 

complete absence of any Pf-positive clinic visits, and children who become parasitemic could provide novel 

immunological benchmarks for vaccines targeting sterile immunity. Career objectives for this K award are:

Objective 1: To advance my knowledge and skills in biostatistics and computational biology and develop 

mathematical models that integrate high-dimensional clinical, epidemiological, parasitological, 

and immunological data in order to predict protection from Pf infection and/or malarial symptoms.

Objective 2: To elucidate mechanisms of immunity to Pf liver- and blood-stage infection by employing 

experimental approaches to complement computational findings, which may require training in 

new laboratory techniques to test specific hypotheses.

Both Dr. Crompton and Dr. Traore are committed to my success as an independent investigator and 

have kindly agreed to allow me access to biospecimens and clinical data from their clinical study for this grant 

proposal. Importantly, I have began to explore ways in which I can study naturally acquired immunity to malaria 

independent of the Malian cohort, including initiating an independent malaria studies in Kenya with guidance 

from Dr. John and institutional support from IUSM.

Candidate’s Plan for Career Development/Training Activities During Award Period

I assembled an interdisciplinary team of mentors who have helped me develop a comprehensive 

training program to ensure that I acquire the skills to become a successful independent investigator 

specializing in computational systems biology with a focus on immunity to Pf infection. This plan includes both 

a didactic and research component, as outlined below, with expected milestones to be completed during the 

K08 award. My effort for the K08 will be 20% clinical and 80% dedicated to research and career development.

Mentors and Advisors: 

Dr. Chandy C. John, Ryan White Professor of Pediatrics and Professor of Microbiology and 

Immunology at IUSM, will act as my primary mentor. He has mentored 44 graduate students, 39 post-doctoral 

fellows, and 7 junior faculty members. Dr. John has received continuous NIH funding since 1999 for studies on 

malaria immuno-epidemiology and severe malaria pathogenesis in Kenya and Uganda. Dr. John has already 

been a key mentor at IU, helping me establish field studies in Western Kenya, where I will lead a project to 

determine the prevalence and parasite densities of asymptomatic P. falciparum infections in communities with 

different malaria transmission intensities. For the proposed K08 project, we will meet individually on a biweekly 

basis to review data and plan research goals in addition to our current joint malaria research group meetings.

Dr. Wanzhu Tu, Professor of Biostatistics in the Department of Biostatistics at IUSM, will be a comentor on this application. Dr. Tu specializes in longitudinal data analyses and semiparametric regression, 

with a focus on modeling of biological processes and developing new analytic tools to better understand 

Contact PD/PI: Tran, Tuan Manh

Candidate Information and Goals for Career Development Page 87
common diseases. Thus, his novel modeling techniques on regularized regression methods, including lasso 

and elastic net, are directly applicable to my research plan. He helped formulate my K08 didactic curriculum 

and will serve as a co-mentor. We will meet monthly for biostatistics and modeling guidance to ensure that I 

become well-versed in advanced generalized linear models and machine learning techniques.

Dr. Lang Li, Professor and T.K. Li Endowed Chair in the Department of Medical and Molecular 

Genetics at IUSM and the Director of the Center for Computational Biology and Bioinformatics, will serve as a 

co-mentor for this proposal. Dr. Li has expertise in pharmacogenomics and uses systems pharmacology 

approaches to elucidate drug interactions and investigate the effects of genetics on drug efficacy and drug 

interactions. His independent research is actively funded by three R01s. Dr. Li has mentored 6 post-doctoral 

fellows and 8 Ph.D. students. He will meet with me monthly during the computational phase of my K08 to 

provide the guidance and resources to properly execute my predictive modeling algorithms.

Dr. Peter D. Crompton, Chief of the Malaria Infection Biology and Immunity Unit in the Laboratory of 

Immunogenetics at NIAID will serve as a co-mentor. I have known Dr. Crompton since 2008, and he served 

as my primary research mentor during my fellowship at NIAID. He provides expertise in human immunity to 

Plasmodium infection. We continue to collaborate on ongoing projects, and four collaborative projects will be 

finalized this year with the manuscripts submitted for publication prior to the start of the current proposal. We 

will have monthly teleconferences and in-person research discussions at 2 conferences per year.

Didactic Training:

Immunology: To remain updated on recent findings and techniques in immunology, I will take the AAI 

Advanced Course in Immunology, a one-week intensive course on new advances in immunology. 

Statistics and Computational Biology: To learn how to develop and apply the appropriate statistical and 

computational models for predicting immune outcomes via integration of high-dimensional biological, 

epidemiological, and clinical data from prospective studies, I will undergo the following didactic regime at IUPUI 

or online: Epidemiology: 1) PBHL E517 Fundamentals of Epidemiology 2) PBHL E601 Advanced 

Epidemiology. Advanced Biostatistics: To advance my knowledge of advanced statistics, I will take: 1) B670 

Linear Regression 2) B670 Categorical Data Analysis 3) B642 Survival Data Analysis 4) B670 Biostatistics 

Computing. Bioinformatics/Computational Biology: To learn how to apply statistical methods to a broad 

range of areas in bioinformatics research, I will take: 1) INFO B646 Computational Systems Biology 2) INFO 

B636 Next Generation Genomic Data Analytics 3) INFO B556 Biological Database Management 4) INFO B529 

Machine Learning for Bioinformatics. All IUPUI courses are 3 credit hours. In addition, I will complete the 

following on-line “Systems Biology Specialization” courses through Coursera which includes: 1) Network 

Analysis in Systems Biology 2) Dynamic Modeling Methods for Systems Biology 3) Integrated Analysis in 

Systems Biology. Each Coursera course requires 6 hours/week of commitment for 6 weeks. To enhance my 

competence in statistical methods for analyzing -omics datasets, I will apply for the intensive one-week Cold 

Spring Harbor Laboratory course “Statistical Methods for Functional Genomics.” 

Writing: Prior to submitting my first R01 application in year 4 and 5, I will improve my scientific writing and 

grantsmanship by enrolling in a scientific writing course and a Grant Writer’s Workshop. 

Timeline of Career Development Activities (percent effort/year where applicable)

Training Activity Year 1 Year 2 Year 3 Year 4 Year 5

Workshops

AAI Immunology Seminar/ CSHL Stats Methods Genomics (2) (2) (0) (0) (0) (0)

Bioinformatics & Computational Biology Courses

Fundamentals of Epidemiology/Advanced Epidemiology (10) (10)

Linear Regression/Categorical Data Analysis (10) (10)

Computational Systems Biology/Biostatistics Computing (10) (10)

Next Gen Genomic Data Analytics/Biological Database Mgmt (10) (10)

Machine Learning for Bioinformatics (10)

Coursera Systems Biology Specialization (on-line) (2) (2) (2) (2) (2)

Conduct of research and ethics

Introduction to Research Ethics course (GRAD G504) (10)

Responsible Conduct of Research and CITI renewals

Grantsmanship and career development

Grant Writer’s Workshop & Scientific Writing Course

Conference Attendance

American Society of Tropical Medicine & Hygiene

Gordon Research Conference/Keystone Symposium

Contact PD/PI: Tran, Tuan Manh

Candidate Information and Goals for Career Development Page 88
Specific Aims: Malaria afflicts ~200 million people yearly, with ~430,000 malaria deaths due to Plasmodium 

falciparum (Pf) (1), underscoring the need for a highly effective malaria vaccine. The first licensed malaria 

vaccine, RTS,S, will provide much-needed reductions in morbidity and mortality. However, its 25.9% efficacy in 

reducing clinical malaria in the target population of African infants (2) leaves ample margin for improvement. 

Other malaria vaccine candidates that performed well in experimental studies also proved less effective in 

pediatric field studies in Africa (3), suggesting that immune factors specific to children in endemic areas may 

influence vaccine-induced responses. Better understanding of immunity to Pf in naturally exposed populations 

will provide insights for improving malaria vaccine design. Despite the established role for Pf-specific IgG in 

conferring immunity to malarial symptoms (clinical immunity) (4, 5), unambiguous immune correlates of 

clinical protection remain elusive (6). Even less is known about immunity to Pf infection (sterile immunity) 

given that years of repeated exposure to the parasite does not reliably confer sterilizing protection from 

parasitemia (7). Systems biology, which relies on computational modeling of large-scale data sets to elucidate 

complex biological networks (8), has been used to predict vaccination outcomes (9-12) and classify diseases 

(13-15) but can also reveal novel insights into host immunity to infection in an unbiased manner (16). 

The goal of this proposal is to use systems biology approaches to elucidate correlates and mechanisms of 

both clinical and sterile immunity to Pf infection in a well-characterized, prospective cohort of Malian children 

living in an area of intense, seasonal malaria transmission (7, 17, 18). We have defined children as clinically 

immune or susceptible to Pf infection based on 3 years of malaria surveillance data. Our initial data has shown 

that clinically immune children at their uninfected baseline have increased B cells and Pf-specific IgG levels—

both features typical of asymptomatic carriers of Pf. Identification of uninfected and asymptomatically infected 

children who have been prospectively defined as clinically immune or susceptible provides an opportunity to 

investigate whether asymptomatic Pf blood-stage infection (BSI) confers clinical immunity or is a consequence 

of clinical immunity. We have also identified a subset of young children who, remarkably, remained free of BSI

as determined by bi-weekly PCR surveillance during 6 months of intense malaria transmission and who 

demonstrated Pf exposure by boosting of Pf-specific IgG, suggesting that these children controlled BSI to 

below PCR-detectable levels—i.e. they developed the closest functional equivalent to sterile immunity 

seen in a naturally exposed population. The present study will take advantage of samples collected from 

this unique cohort to identify immune parameters that characterize and best predict clinical immunity (no 

symptoms with BSI) or apparently sterile immunity (no evidence of active BSI by PCR despite evidence of Pf

exposure). Our overall hypothesis is that children who have acquired either clinical or sterile immunity to Pf

have distinct pre-infection immune profiles than predict Pf infection or malaria outcomes. 

Specific Aim 1: Identify immune parameters predictive of clinical immunity to Pf infection (protection 

from symptomatic BSI) and sterile immunity to Pf infection (protection from BSI). 

We will perform transcriptomics, multiplex cytokine analysis, Pf-specific antibody profiling, and flow 

cytometry on baseline blood samples and apply these parameters along with parasitological, demographic, 

and genetic data to both machine learning algorithms and statistical models to determine which parameters 

best predict clinical or sterile immunity. Although the goal is to identify novel predictors and signatures of both 

clinical and sterile immunity in an unbiased manner, based on previous data, we hypothesize that Pf-specific 

IgG antibodies, a B-cell signature, and Pf BSI status will be significant predictors of clinical immunity, whereas 

either a Type I or Type II interferon signature will predict sterile immunity. 

Specific Aim 2: Compare cellular, molecular, and Pf-specific IgG reactivity profiles in the blood of 

children with clinical immunity vs. children with sterile immunity and relate these profiles and immune 

outcomes to the in vitro parasite-inhibitory activity of their plasma. 

To determine biological signatures that might define clinical and sterile immunity, we will directly 

compare transcriptomic, cytokine, Pf-specific antibody reactivity, and flow cytometry data between the two 

immune classes. We hypothesize that the clinically immune signature will be biased towards B-cells and have 

a predominantly blood-stage specific antibody profile, whereas a signature of sterile immunity will be driven by 

interferon responses and an antibody profile targeting both pre-erythrocytic and blood-stage antigens. We will 

quantify the ability of plasma from children in our study to inhibit parasite invasion of human hepatocytes and 

erythrocytes in vitro and determine whether invasion-inhibitory activity in plasma correlates with protection from 

BSI or symptomatic BSI after accounting for confounding variables. We hypothesize that plasma from sterilely 

immune children will inhibit parasite invasion of both hepatocytes and erythrocytes in vitro and that this activity 

will correlate with increased IgG reactivity intensity against both pre-erythrocytic and blood-stage antigens. 

Taken together, this work will enhance our understanding of natural immunity to both malarial disease 

and Pf infection and may identify novel predictors and mechanisms of immunity to Pf within the vaccine target 

population, thus informing the rational design of malaria vaccines for children in Africa.

Contact PD/PI: Tran, Tuan Manh

Specific Aims Page 89
Contact PD/PI: Tran, Tuan Manh

Research Strategy

1. Significance 

 Malaria is a global health burden that afflicts ~200 million people annually (1). Plasmodium falciparum

(Pf), the deadliest of human malaria parasites, is responsible for the overwhelming majority of ~438,000 

malaria deaths, primarily in children under 5 years of age (1). A highly effective malaria vaccine is widely 

viewed as a much-needed tool for reducing malaria in endemic areas where healthcare delivery and vector 

control strategies are often disrupted by political conflict, natural disasters, and the ever-present potential for 

epidemics of rapidly transmissible viruses such as Ebola that can divert scarce resources from malaria control 

efforts (38). If licensed, the first malaria vaccine, RTS,S, will partially reduce the burden of malaria in certain 

endemic areas, but its 25.9% efficacy in the target population of African infants (2) leaves ample margin for 

improvement. Other malaria vaccine candidates that initially performed well in clinical trials with malaria-naïve 

adults have subsequently performed poorly in African children (3), suggesting that parasite and immunological 

factors specific to children in endemic areas may influence vaccine efficacy. Thus, a better understanding of 

immunity to malaria in naturally exposed populations may provide insights for improving malaria vaccine 

design. 

 Immunity to Plasmodium is inextricably linked to the parasite life cycle. After a human has been 

inoculated with Pf sporozoites by the bite of an infected female Anopheles mosquito, the parasite can, within 

minutes, migrate via the bloodstream to invade liver hepatocytes, where they develop and replicate for ~7 

days, after which they rupture from hepatocytes as merozoites and begin the blood stage of infection. Pf bloodstage infection (BSI) begins as low-level, asymptomatic parasitemia which can rapidly progress to a spectrum 

of clinical illness ranging from uncomplicated malaria (defined as confirmed BSI with symptoms such as fever 

but in the absence of severe criteria) to severe malaria (criteria includes but not limited to hyperparasitemia, 

impaired consciousness, convulsions, or severe anemia) to death (39). In areas of intense malaria 

transmission, immunity to Pf infection can also be viewed as a sequential spectrum (40). Natural immunity is 

acquired to severe, life-threatening disease after a young child survives 1-2 severe malaria episodes early in 

life, but immunity to uncomplicated malaria requires years of repeated Pf infections (40). Thus, reliable clinical 

immunity, or immunity that prevents malarial symptoms, is generally not acquired until adolescence in 

individuals living in highly endemic areas. Importantly, such intense exposure to Pf in endemic settings does 

not readily confer sterile immunity (immunity that prevents establishment of BSI) even as children approach 

adulthood (7). 

 It is well established that Pf-specific IgG confers clinical immunity to malaria (4, 5); however, 

unambiguous targets of IgG-mediated protection still remain elusive (6). Similarly, Pf-elicited cellular interferongamma (IFNγ) responses have been associated with clinical immunity to malaria in humans (41-43), but 

specific cellular correlates of either naturally acquired or vaccine-induced immunity have yet to be validated 

across multiple settings. Furthermore, as IFNγ responses can also trigger pathological inflammation, the 

mechanisms required for maintaining a balance between immunity and immunopathology are not fully 

understood. Sterile immunity has been well studied in experimental models of Plasmodium infection. In mice 

and non-human primates, IFNγ plays a critical role in sterile protection afforded by immunization with irradiated 

sporozoites (44-46). More recently, type I IFN responses generated during liver-stage infections were shown to 

reduce Plasmodium liver infection load and delay the appearance of BSI (47, 48). Another study showed that 

antibodies generated against α-gal present on gut commensal bacteria can target sporozoites intradermally to 

prevent Plasmodium infection (26). In contrast to animal studies, much less is known about the mechanisms of 

sterile immunity in humans given the lack of accessible biomarkers specific for liver-stage infection that would 

help distinguish the relative contributions of effective liver-stage immunity from early blood-stage immunity in 

controlling initial parasitemia. Because neither predictors of clinical immunity nor sterile immunity to Pf infection 

in humans are known, understanding the mechanisms responsible for differential immune outcomes after Pf 

exposure and infection in children residing in endemic settings will guide efforts to develop malaria vaccines 

that achieve better response in the primary target population.

 We are conducting an ongoing cohort study in Kalifabougou, Mali where Pf transmission is intense and 

seasonal. In this study, we prospectively monitor children for both Pf infection and febrile malaria episodes, 

allowing us to categorize children by the number of febrile malaria episodes over three malaria transmission 

seasons. During the first season, we collected dried blood spots (DBS), plasma, and whole-blood RNA at biweekly active surveillance visits and sick visits, allowing us to 1) retrospectively detect each child’s first Pf BSI 

of the season by PCR of archived DBS and 2) perform whole-blood transcriptomics on uninfected and infected 

samples. Our initial results using clinical data over the first malaria season demonstrated that a 

Research Strategy Page 90
Contact PD/PI: Tran, Tuan Manh

 molecular signature of whole blood prior to infection associates with clinical immunity to Pf

infection. Furthermore, a subset of children never demonstrated detectable BSI despite bi-weekly PCR of 

fingerprick blood samples. Importantly, these children showed evidence of having been exposed to infective 

mosquito bites as demonstrated by boosting of antibodies to pre-erythrocytic Pf antigens, which, taken 

together, suggests that they approached sterile immunity, i.e., BSI was never established or never achieved 

PCR-detectable levels. These initial data provided proof-of-concept that baseline host-immune 

molecular signatures could differentiate prospectively defined immune phenotypes, serving as a basis 

for further studies to not only validate said signatures predictive of clinical immunity but also to 

determine signatures predictive of sterile immunity. Thus, we hypothesize that differential host immune 

profiles at the pre-infection baseline can influence the immune response during subsequent Pf infection and 

predict whether the host will be protected from BSI or protected from disease. 

2. Innovation 

The innovation within this proposal lies in: 1) the availability of longitudinally collected biospecimens 

(plasma/whole-blood RNA/DBS/PBMCs) that are linked to >3 years of prospective clinical, parasitological, and 

epidemiological data in a cohort of children living in a village with intense malarial transmission 2) the use of 

unbiased systems biology approaches to assess differences in gene expression, antibody, and cellular profiles 

between clinical phenotypes followed by complementary experiments aimed at evaluating the functional basis 

for differences in host immune outcome and 3) the identification of a unique subset of children who were 

protected from BSI despite evidence for exposure to infective mosquito bites, facilitating the rational evaluation 

of host factors that may confer apparently sterile immunity. The proposed work will determine whether clinical 

or apparently sterile immunity to natural Pf infection can be predicted by host differences prior to 

exposure/infection and may provide valuable targets for assessing immune correlates of protection in malaria 

vaccine studies. The trove of biospecimens and clinical data provides a unique opportunity to rationally identify 

baseline biomarkers predictive of immunity to Pf using an unbiased, systems approach. 

3. Approach 

3.1. General Strategy: Children living in malaria-endemic areas gradually acquire immune mechanisms that 

protect against Pf. In this well-characterized cohort, we defined children as clinically immune, sterilely immune, 

or susceptible to Pf. Our general hypothesis proposes that these three groups can be distinguished by global 

analyses of host immune factors at baseline, prior to the first Pf exposure of the malaria season. Our overall 

strategy is to analyze biospecimens collected from children differing in levels of Pf immunity at baseline or 

during/after incident Pf exposure to assess differential host responses to the Pf parasite. 

3.2. Specific Aim 1: Identify immune parameters predictive of clinical immunity to Pf infection 

(protection from symptomatic BSI) and apparently sterile immunity to Pf infection (protection from 

BSI). 

3.2.1. Rationale and Preliminary Data: Our preliminary data has shown that gene expression profiles of 

whole blood obtained at the Pf PCR-negative baseline differed between children who remained asymptomatic 

during their first Pf infections of the ensuing malaria season (clinically immune) versus children who presented 

with febrile malaria during their first Pf infection of the season (susceptible, Fig. 1A). Pathways and regulator 

network analyses of differentially expressed genes prior to infection suggested that a 

signature associated with clinical immunity to incident BSI during the 6 month follow-up 

period (Fig. 1B). Clinically immune children had higher Pf-specific antibody levels and 

compared to susceptible subjects at pre-infection baseline (Fig. 1C), which are features typically found in 

another group of individuals who are protected from febrile malaria attacks presumably due to enhanced 

immunity: asymptomatic, long-term carriers of Pf (Fig. 1D) (18, 49). Two intriguing hypotheses may explain the 

relationship between clinical immunity to BSI and asymptomatic carriage of BSI: 1) elevated Pf-specific IgG 

levels, signature observed in clinically immune children at their 

uninfected baseline are actually driven by recent or occult BSI below the detection limit of our PCR assay, 

which would explain why their immunological profile mirrors that of asymptomatic, chronic Pf carriers or 2) a 

distinct, malaria-protective immune profile is established first, which then predisposes children to clinically 

silent infections that go undetected and thus untreated. To test the first hypothesis, we will re-interrogate for 

occult BSI using a recently developed ultrasensitive quantitative real-time PCR (qPCR) assay that improves 

sensitivity by as much as 30-fold relative to our original PCR assay (50). For the second hypothesis, we must 

Research Strategy Page 91
Contact PD/PI: Tran, Tuan Manh

first determine whether the malaria-protective, signature that we observed at 

baseline is a unique feature of clinical immunity in uninfected children or if all clinically immune children, 

irrespective of asymptomatic BSI status, share pertubations in immunological pathways that might predict host 

control of malarial symptoms. Understanding the relationship between asymptomatic BSI and clinical immunity 

to malaria will clarify whether asymptomatic BSI confers/maintains clinical immunity or is a consequence of 

prior acquisition of immunity, which has important implications for malaria vaccine studies (51) and eradication 

efforts (52). 

In our first Kalifabougou study, we observed no age-related differences in time-to-first Pf infection 

(irrespective of symptoms) of the season among individuals aged 4-25 years of age and concluded that there 

was no evidence for acquisition of sterile immunity with increased duration of malaria exposure. Children <4 

years of age were excluded from this initial study, because we observed that they had decreased prospective 

risk of Pf infection, with ~20% never becoming positive for Pf by bi-weekly blood PCR despite 6 months of 

intense malaria transmission. This effect persisted even after separating children <6 months of age to account 

for maternal IgG (Fig. 2A). We hypothesized that the decreased infection risk was due to decreased exposure 

to infective mosquito bites, perhaps due to maternal behavioral factors (swaddling, etc.). To better address the 

question of Pf exposure, we asked whether these children had boosting of plasma antibodies after the 6-month 

malaria season specific for 1) a salivary gland antigen of the primary Pf vector Anopheles gambiae, gSG6; 2) 

pre-erythrocytic Pf antigens; or 3) blood-stage Pf antigens either by traditional ELISAs or Pf protein microarray, 

as increased antibodies would suggest vector, pre-erythrocytic, and blood-stage exposure, respectively. 

Surprisingly, 12 children who had complete 7-month follow-up and tested negative for Pf infection by PCR 

every 2-weeks and at sick visits also showed antibody boosting to ≥1 pre-erythrocytic antigen or gSG6 (53), 

Figure 1. Differences in immune and 

susceptible children at healthy, uninfected 

baseline. (A) MA smearplot showing the logfold change (FC) between the 2 groups 

against the log counts per million (CPM) as 

determined by RNA-seq. Red points indicate 

differentially expressed genes (DEGs) with a 

false discovery rate (FDR)<5% determined 

using a generalized linear model in edgeR. (B) 

DEGs in A with FDR<5% were applied to 

pathways and upstream regulator analysis. 

Shown are top significant immune pathways. 

BH: Benjamini-Hochberg. A |z-score| >2 with 

P<0.01 is considered significant. Differences 

between % B cells and Pf-specific IgG 

responses are shown between (C) clinically 

immune and susceptible children at uninfected 

baseline and between (D) asymptomatic, Pf

PCR (+) and PfPCR (-) children. *P<0.05; 

**P<0.01; ***P<0.001. Significance determined 

by t test or Wilcoxon test as appropriate.

Figure 2: Evidence supporting apparently sterile immunity in a subset of children in the Kalifabougou cohort. (A) A proportion of children, 

predominantly <4 years of age, remained free of Pf infection after 6 months of intense malaria transmission and bi-weekly, retrospective determination 

of their Pf infection status by PCR. Significance testing was by log-rank analysis for all groups. (B) Heatmap showing the log ratio of post-malaria 

season (January 2012) and pre-malaria season (May 2011) antibody responses by ELISA or a protein array containing 1,087 Pf antigens for 12 sterilely 

immune (never infected, rightmost columns) and 75 non-protected children. Red indicates that antibody responses increased after the malaria season. 

Research Strategy Page 92
Contact PD/PI: Tran, Tuan Manh

providing evidence of Pf exposure and suggesting apparently sterile immunity to Pf infection (Fig. 2B). This 

protected phenotype, rarely seen in studies conducted in areas of intense Pf transmission, offers a unique 

opportunity to investigate the mechanisms of sterile immunity in humans naturally exposed to Pf malaria. 

3.2.2 Methodology 

a) Study site, subjects, and available biospecimens: We will use cryopreserved biospecimens collected from

subjects who are enrolled in an ongoing observational cohort study in the village of Kalifabougou, Mali. Here, 

malaria transmission is intense and seasonal from June through December. Biospecimens used in this 

proposal are from the first malaria season (May 2011-January 2012), but prospective clinical data has been 

ongoing. Subjects with the hemoglobin genotypes HbS/C and subjects co-infected with Schistosoma 

haematobium have been excluded from the current proposal as these factors can affect malaria risk (18, 54). 

The case definition for a malaria episode is an axillary temperature >37.5°C and a parasite density by blood 

smear of >500 asexual parasites/μl, a threshold chosen to provide sensitivity in diagnosing malaria while 

maintaining specificity in a semi-immune population who may develop fevers from other pathogens. Our 

preliminary study evaluated 20 children meeting a strict definition for clinical immunity: incident BSI with no

malaria episodes and no receipt of anti-malarials during the first malaria season (Fig. 1A). Given that subjects 

meeting this strict definition of no episodes have already been evaluated, the current proposal defines clinically 

immune as ≤2 malaria episodes over 3 years and susceptible as ≥4 episodes over 3 years. Children with 3 

malaria episodes over 3 years are interdeterminate and excluded. The current definition treats clinical immunity 

more as a continuum and allows for partial immunity and the development of the occasional fever. Class 

definitions and sample availability are shown for the clinical (Table 1) and sterile immunity (Table 2) studies. 

Table 1: Clinical Immunity Class Definitions and Available Samples (n) 

Class Description Definition n

Time

Point

Samples

Available

A Clinically Immune, Uninfected ≤2 malaria episodes over 3 years; Pf PCR (-) at baseline 10 May 2011

(premalaria 

season)

PBMCs, 

DBS,RNA, 

plasma, 

pellet

B Clinically Immune, Infected ≤2 malaria episodes over 3 years; Pf PCR (+) at baseline 47

C Susceptible, Uninfected ≥4 malaria episodes over 3 years; Pf PCR (-) at baseline 18

D Susceptible, Infected ≥4 malaria episodes over 3 years; Pf PCR (+) at baseline 21

Table 2: Sterile Immunity Class Definitions and Available Samples 

Class Description Longitudinal Pf PCR status

during the 2011 malaria season

Pf, vector 

exposure status

Number of 

available 

subjects

Samples available by time 

point

E

apparently 

sterile immunity

(protected from 

BSI)

Negative at every 2 week 

surveillance visit and passive 

(sick) visit

Boosting of Abs

to ≥1 Pf preerythrocytic 

antigen or gSG6 

during first 

malaria season

12 (11 with 

boosting to ≥1 Pf

pre-erythrocytic 

antigen ± gSG6

Baseline (May 2011): 

PBMC, whole blood RNA, 

plasma (2ml), DBS

Bi-weekly time points: 

whole-blood RNA, plasma 

(50 μl), DBS

F non-protected Converted from negative to 

positive at least once 75

b) Evaluation of additional erythrocyte variants that may affect malaria risk: Although HbS/C individuals have

been excluded in this proposal, we will control for the presence of other erythrocyte variants that might affect 

malaria risk. ABO blood group typing has been performed for our cohort, and we will genotype for the most 

common α thalassemia and glucose-6-phosphate dehydrogenase deficiency variants present in Mali (54, 55). 

c) Re-interrogation of baseline samples by ultra-sensitive quantitative real-time PCR: To verify that clinically

immune groups from the our preliminary study and the current proposed study were not misclassified as 

uninfected at baseline, we will re-interrogate all samples using an ultrasensitive qPCR assay (50) with genomic 

DNA (gDNA) extracted from cryopreserved cell pellets obtained from ~200 μl of whole blood. This assay 

targets the TARE-2 repeat region in the Pf genome and has a sensitivity of 0.03-0.12 parasites/μl, which is 10-

30x more sensitive than the method we originally used to determine Pf infection status (1 parasite/μl) (7, 56). 

d) Determining kinetics of P. falciparum specific IgG Abs by protein microarray: We will measure Pf-specific

IgG responses using protein array technology developed by Dr. Philip Felgner (University of California 

Irvine) as previously described (57). This technique involves probing plasma samples to glass slides spotted 

with 1,087 recombinant Pf antigens, allowing either single-antigen, stage-specific, or general assessments of 

Pf-specific IgG reactivity. 

For the clinical immunity study, Pf-specific IgG responses will be measured at the uninfected baseline, and 

differential reactivity between classes will be assessed using the empirical Bayes method in the limma package 

(58). Sterilely immune children, by definition, do not have a Pf PCR positive timepoint, and biomarkers of 

Research Strategy Page 93
Contact PD/PI: Tran, Tuan Manh

human liver-stage infection do not exist. Thus, for the sterile immunity study, we will rely on the kinetics of host 

antibody response to Pf to estimate the time of the first Pf exposure of the season (referred to as “incident 

exposure”). We will take advantage of the fingerprick blood specimens (whole-blood RNA/plasma) collected biweekly during the malaria season and determine longitudinal antibody responses. The 2-week timepoint 

showing the first significant increase in the sum intensity of antibody responses to pre-erythrocytic antigens 

(e.g. CSP, TRAP, LSA-1) from baseline (T0) will approximate the incident exposure (T1). Samples from 

subjects who had documented Pf infection during the season (Class F) will be used as a control, as it is 

expected that T1 will coincide with the time point before or during incident infection. 

e) Whole-blood transcriptomics: We will use RNA-seq of fingerprick whole-blood samples collected directly in

Tempus (ThermoFisher) to assess differential gene expression. Total RNA will be extracted, and rRNA and 

globin mRNA will be removed with the Globin-Zero rRNA Gold kit (Illumina). RNA-seq libraries will be prepared 

(25 million paired-end 2x75 bp reads per sample) and sequenced on a NextSeq 500 (Illumina). Samples will be 

randomized and processed at the same time to avoid batch effects. Reads will be mapped to the reference 

human genome (hg38), and count data will used for differential gene expression analysis using edgeR (59), 

DESeq2 (60), and limma-voom (58). Both edgeR and limma-voom allow for adjustment of any significant 

baseline differences between groups (e.g. possible age differences) if needed. Contrasts will be set up as 2-

way comparisons between the classes (Tables 1-2) or as nested factorial designs (see below). 

For the clinical immunity study, transcriptomics will be performed on whole blood collected in May 2011, 

prior to the first malaria season. The Class A vs. C contrast will address baseline transcriptional differences 

that may define clinical immunity prior to Pf infection, while the Class A vs. B contrast will be important to 

determine the effects of baseline asymptomatic infection on clinical immunity. For the sterile immunity study, 

transcriptomics will be performed on whole-blood samples collected from protected (E) and non-protected 

(F) children at T0 and T1. The contrast of Class E.T0 vs. F.T0 will determine if there are any baseline 

transcriptional differences between protected and non-protected children. The contrast of (E.T1 - E.T0) - (F.T1 

- F.T0) with paired samples will determine transcriptional differences in host responses to incident Pf exposure 

between classes. Genes with an absolute fold-change of >1.5 and a false discovery rate (FDR) of <5% will be 

considered differentially expressed. Geneset testing will be performed within edgeR using the roast and 

camera functions (both in the limma package). Genes with a FDR <5% will be used in Ingenuity pathways 

analysis and modular analysis. We will use qPCR to confirm gene expression for selected genes. 

Table 3 shows conservative power estimates for identifying 80% of DEGs whose absolute fold change is 

>2 at samples sizes for each 2-group comparison, assuming a nominal FDR of 5% and gene expression levels 

and dispersions estimated from our previous RNA-seq data. The statistical power of differential gene analysis 

(DGE) analysis is limited by the smaller sample sizes of Classes A and E. Thus, comparison of smaller groups 

will be considered exploratory. 

Table 3: Power table for RNA-seq DGE using edgeR and the PROPER package (61) (100 simulations) 

Group 1 (n1) Group 2 (n2) Actual FDR Marginal Power Avg # of True 

Discoveries

Avg # of False 

Discoveries

A (10) B (47) 0.048 0.53 270 13

A (10) C (18) 0.110 0.34 170 21

B (47) D (21) 0.055 0.64 320 18

C (18) D (21) 0.078 0.52 260 22

E (12) F (75) 0.045 0.63 310 15

A+B (57) C+D (39) 0.054 0.78 390 22

A (10) E (12) 0.16 0.20 100 19

f) Multi-parameter flow cytometry and multiplex cytokine analysis: Flow cytometric analysis (FACS) will be

performed on cryopreserved PBMCs collected in May 2011 (contemporaneous with the RNA samples at T0) to 

determine expression of and cytokine production among specific cell subsets. 

Specifically, we will determine the relative proportion of B cells (CD19+), CD3+CD4+ T cells, CD3+CD8+ T 

cells, NK cells (CD56+), monocytes (CD14+) and γδ T cells (TCR γδ+) and perform intracellular staining for 

IFNγ, IL-6, TNF, Additional markers will be assessed based on the results of the 

transcriptomic analysis. Samples will be acquired on a BD LSRII flow cytometer and analyzed using FlowJo. 

Cytokine profiling of baseline plasma will also be performed for all classes using a multiplex cytokine profiling 

platform (BioRad) to test a broad panel of cytokines involved in inflammation that includes Type I/II interferons 

(IFNs), TNF, IL-1β, IL-6, and . Significance group differences will be determined by t tests or 

Wilcoxon signed-rank tests as appropriate with Benjamini-Hochberg adjustments for multiple testing. 

g) Genetic analysis of P. falciparum isolates from clinically immune and susceptible children: To address the

possibility that differences in clinical outcomes between immune and susceptible children are due to parasite 

rather than host factors, we will evaluate genetic differences between Pf isolates. We will extract gDNA from 

Research Strategy Page 94
Contact PD/PI: Tran, Tuan Manh

cryopreserved blood pellets at all Pf PCR-positive visits and perform Pf genotyping using standard protocols 

for neutral loci Pf microsatellite analysis. 

h) Multi-parameter statistical modeling and machine learning to predict clinical or sterile immunity: Given the

lack of immune correlates of clinical or sterile protection from Pf, the overall goal of these analyses is to 

determine which variables examined at baseline best predicts clinical or sterile immunity. With the guidance of 

Drs. Tu and Li, I will use machine learning approaches to determine which variables (features) from 

demographic (i.e. age, gender), epidemiological, erythrocyte variant, parasitological (including baseline BSI), 

transcriptomic, FACS, multiplex cytokine, and Pf-specific IgG data best predicts clinical or sterile immunity in 

two independent models. In the clinical immunity model (Classes A+B, C+D), we will include all constant 

features and features collected at baseline. The outcome will be clinical immunity or malaria susceptibility. The 

sterile immunity model (Classes E, F) will include transcriptomic and Pf-specific Ab features collected at T1 in 

addition to all constant and T0 baseline features. The outcome will be sterile immunity or non-protected. We 

will first focus on regularized regression methods that consider all features simultaneously while also providing 

automatic feature selection (e.g. lasso, elastic net). Of these, elastic net is ideal for our study: it provides both 

automatic feature and grouped selection and performs well when the number of features >> number of 

samples and when the features are highly correlated (62). We will also test machine learning algorithms (e.g. k 

nearest neighbors, random forest, linear discriminant analysis). For algorithms without automatic feature 

selection, we will pre-select features using recursive feature elimination. We will perform model-specific 

parameter training and use repeated k-fold cross-validation to estimate the prediction error for each model. 

This approach ensures that we select models with the most accurate and stable predictions for our data set. 

The sample sizes for this proposed study are pre-determined by the number of subjects meeting the 

selection criteria for this study with available samples (Table 1). Elastic net analysis of data simulated from our 

previous experimental data sets and group sample sizes of 57 and 39 (representing A+B and C+D) 

consistently identified ≥20 parameters from ~8300 features that can predict a binomial outcome with a crossvalidated mean square error of 0.055-0.060 after 50 simulations. To further increase sample sizes and improve 

prediction accuracy, we will include data from the previous study (Fig. 1A). The definition of “clinically immune” 

in our current proposal (≤2 malaria episodes over 3 seasons) differs from the definition for the previous study 

(no malaria episodes over one season). Thus, we have reclassified the samples from the first study to match 

the definitions in the current proposal, adding 28 Class A and 33 Class C samples and allowing us to use 

samples from one study as a training set and the other as a test set or include all in a cross-validation scheme. 

3.2.3. Expected outcomes – Aim 1 

This work will attempt to validate findings in our previous study, which found increased immune activation 

in clinically immune children compared to susceptible children prior to their first Pf BSI of the malaria season, 

and determine if asymptomatic Pf BSI, which also is associated with decreased prospective risk of febrile 

malaria attacks, influences baseline immune activation. We previously showed that clinically immune children 

had and enhanced Pf-specific IgG responses compared 

to susceptible children at their uninfected baseline, similar to asymptomatic, chronic carriers of Pf, but did not 

perform direct comparative transcriptomics between these groups. Of note, we do not expect to detect many, if 

any, occult infections by ultrasensitive qPCR as most of the children who were PCR negative at baseline had 

multiple, consecutive negative PCRs prior to their first positive PCR. 

We will address our general aim of determining genome-wide, whole-blood predictors of clinical immunity 

to Pf infection with an emphasis on investigating whether the presence of asymptomatic Pf BSI significantly 

influences the immunological profile of clinical immunity at baseline. Overall, we expect to validate our previous 

findings and find signature in both immune classes (A and B) compared 

to the susceptible classes (C and D) by transcriptomics and FACS, irrespective of infection status. Although we 

anticipate that the relative will be similar between Class A and B, the 

 should differ qualitatively and quantitatively given evidence that asymptomatic infections have been 

associated with changes in . 

We expect that regularized regression methods such as elastic net give us the best chance at determining 

a correlate of clinical protection from high-dimensional, multi-parameter data. We anticipate that baseline 

parameters of Pf-specific IgG response, B-cell percentage, and Pf BSI status to be positive predictors of 

clinical immunity given their correlation to previous malaria exposure, but we hope to gain novel insight as to 

which of the experimentally measured variables have the strongest independent effects on clinical immunity. 

Based on our experience with the previous dataset, we anticipate that certain features related to immune 

activation would be specifically enhanced in a majority of clinically immune children. 

Research Strategy Page 95
Contact PD/PI: Tran, Tuan Manh

For the sterile immunity analyses, we anticipate that IgG responses against pre-erythrocytic antigens will 

show variable increases during the months of intense malaria transmission, allowing us to identify an 

appropriate T1 time point for our paired RNA-seq studies. Given the evidence that systems-based approaches 

can reveal unanticipated differences in host immune profile predictive of subsequent responses to 

immunological perturbation [Fig. 1A, (11)], we expect to see moderate whole-blood gene expression variability 

at T0 that will roughly align with the dichotomous classes E and F. We hypothesize that baseline Type I/II IFN 

activation will be seen in sterilely immune children relative to non-protected children based on the evidence 

that these pathways are involved in host control of the parasite during the pre-erythrocytic stages (47, 48). 

Furthermore, IFN pathways activation will likely be enhanced during incident Pf exposure (T1). Because the E 

vs. F comparison has a marginal power of 62% for observing ~300 differentially expressed genes (DEGs) at 

≥2–fold change (Table 3), our genome-wide analysis will likely reveal novel insights into the genes associated 

with sterile immunity. We expect multiplex cytokine and FACS data to corroborate the transcriptomic findings 

provided that these assays are sufficiently sensitive to detect group differences. Should we identify a cytokine 

signature, FACS analysis will be critical for identifying the cell subset responsible for cytokine production. 

3.2.4. Anticipated Problems and Limitations – Aim 1

An important limitation of this work is the lack of power to detect subtle gene expression differences 

between groups for comparisons involving Class A (n= 10). If DEGs were not detected between Class A vs. B 

and Class C vs. D, we would conclude that asymptomatic Pf infection at baseline does not have a large effect 

on baseline gene expression profiles for either clinically immune or susceptible children. We would then 

perform a secondary analysis in which the two immune classes, Class A and B, are combined, giving us larger 

sample sizes (clinically immune = 57, susceptible = 39) with a marginal power of 78% to detect a ≥2-fold 

difference between groups (Table 3). Small group sizes will also preclude more robust class prediction using 

all parameters. Inclusion of the previous study’s independent dataset adds 28 Class A and 39 Class C subjects 

and will further improve our ability to accurately classify subjects. 

Classes A and B would also be combined into a single group if validation of prior PCR results with ultrasensitive qPCR reveals occult infection in clinically immune children previously labeled as uninfected. Such a 

scenario would provide a plausible, biological explanation for inflammatory activation and enhanced antibody 

responses previously seen in the clinically immune group (strict definition) and support the argument that 

asymptomatic parasitemia confers or maintains clinical immunity rather than being a consequence of immunity. 

Here, we would take advantage of having qPCR data for all immune children (Classes A+B, n=57) to address 

whether baseline parasite density correlates with changes of immunological markers and malaria outcomes. 

In vivo biomarkers of Pf liver-stage infection have yet to be identified because 1) Plasmodium liver-stage 

infection is clinically silent and 2) host responses are likely confined locally to infected hepatocytes (47). Any 

changes in peripheral blood cells due to pre-erythrocytic Pf exposure are likely transient and difficult to detect, 

especially in an endemic pediatric population where blood can only be sampled at a certain resolution (here, 

every two weeks) for ethical and practical reasons. The main emphasis here is the prediction of sterile 

immunity by global analysis, with the primary biological parameters of interest being the ones determined using 

baseline (T0) samples, a strategy that has a moderate likelihood of success (Table 3). Attempting to detect 

biological changes at T1 carries higher inherent risk given that T1 is based on antibody response kinetics with 

only 2-week resolution and only represents the most proximal point to liver-stage infection among available 

time-points. This strategy might miss transient or subtle biological changes in blood and exhibit high intrasubject variability due to the unknown duration between actual Pf infection and T1. Despite these limitations, 

detecting a signal in any T1 sample will be informative as it would be the first time any surrogate marker 

suggestive of natural Pf liver-stage or initial blood-stage infection has been detected in a child living in an 

endemic area. Such a marker will have to be further evaluated for confounding by co-incident infections and 

validated in controlled human malaria infection studies. 

3.3. Specific Aim 2: Compare cellular, molecular, and Pf-specific IgG reactivity profiles in the blood of 

children who are clinically immune vs. children with sterile immunity and relate these profiles and 

immune outcomes to the in vitro parasite-inhibitory activity of plasma 

3.3.1. Rationale and Preliminary Data: Results from Aim 1 provide an opportunity to directly compare the 

immunological profiles of clinically and sterilely immune children prior to infection. Global analysis of all 

measured parameters (e.g. gene expression, FACS, Pf-specific IgG reactivity) from pre-perturbation samples 

may provide insights as to what type of immune profile could distinguish between sterile and clinical immunity 

or if both types of protection share common immune pathways. Whereas clinical immunity to Pf infection is 

Research Strategy Page 96
Contact PD/PI: Tran, Tuan Manh

dependent on various facets of immunity elicited during BSI, sterilizing 

immunity to Pf infection could theoretically be achieved at four points along 

the parasite’s intended path towards establishing BSI in the human host: 1) 

intradermally (immediately after inoculation of sporozoites by the mosquito) 

2) in the blood/liver prior to hepatocyte invasion 3) during intrahepatocytic

parasite development and 4) during the initial blood-stage inoculum when 

merozoites first exit the liver. Blood components could potentially inhibit the 

parasite at points 1, 2, or 4. Although Pf stage-specific IgG reactivity 

profiles from protein arrays might provide clues as to whether anti-parasite 

effects are mediated at the pre-erythrocytic stage (points 1 and 2) or during 

the blood-stage (point 4), inhibition of parasite invasion assays can 

provide functional evidence of pre-erythrocytic or blood-stage mediated 

sterile protection. We recently performed a pilot study in collaboration with 

Dr. Sangeeta Bhatia and Sanaria to assess the ability of plasma from 

individuals from Kalifabougou (n=24; distinct from current study) to inhibit 

invasion of sporozoites into human hepatocytes using a microscale 

human liver platform developed by her lab that recapitulates complete Pf

liver-stage development in vitro (65, 66). 

 

Similarly, we previously determined that 

IgG specific for the blood-stage antigen PfRH5 inhibited parasite growth 

in vitro using standardized growth inhibition assays (GIAs)(17), but at concentrations far greater than those 

occurring in malaria-immune Malians, implying that PfRH5-specific IgG levels only partially explain protection 

from clinical malaria. Parasite inhibitory activity exhibited by plasma components in these functional assays will 

be related back to Pf antigen-specific IgG reactivity profiles to identify new correlates and also incorporated 

into the multi-parameter models to assess the contribution of in vitro inhibitory activity to immune outcomes. 

3.3.2. Methodology – Aim 2 

a) Qualititiave and statistical comparison of clinical and sterile immunity: To determine biological signatures

that might define clinical and sterile immunity, we will directly compare transcriptomic, Pf-specific antibody 

profiling, cytokine, and FACS data between clinically and sterilely immune children using statistical methods 

considered standard for each dataset (e.g. edgeR for RNA-seq, empirical Bayes for protein arrays) and adjust 

for multiple testing. Geneset enrichment, pathways, and modular analysis will be performed with transcriptomic 

data to gain insight into cellular processes and mechanisms that may differentiate clinical vs sterile immunity. 

b) Functional assessment of plasma from children with different immune outcomes: To better understand the

mechanisms underlying the immune phenotypes, we will assess the ability of baseline plasma collected from 

clinically immune, sterilely immune, and susceptible children to inhibit parasite invasion into human 

hepatocytes and erythrocytes using established methods. To assess differential inhibition of hepatocyte 

invasion and/or intrahepatocytic development by Pf NF54 sporozoites, plasma from protected or non-protected 

children will be added to the co-culture before or after establishment of the intrahepatocytic stage. Detection of 

sporozoite entry will be performed by fluorescence microscopy to assess intracellular sporozoites using antiPfCSP antibody, and the progression rate of liver-stage development will be measured by determining the 

percentage of Pf exoerythrocytic forms within hepatocytes over time as described (65, 66). Sterile or 

parasitemia-reducing immunity conferred by inhibition of the merozoites during the initial blood-stage inoculum 

is a distinct possibility given that boosting to prototypical Pf blood-stage antigens was also observed in Class 

E.T0 plasma (Fig. 2B). Therefore, to assess the ability of plasma to inhibit blood stage growth, we will use a 

well-established, standardized protocol for GIAs, in which we compare growth-inhibitory activity of IgG purified 

from the plasma of sterilely immune, clinically immune and susceptible individuals. 

c) Correlating parasite-inhibitory activity to Pf antigen-specific IgG reactivity: Plasma parasite-inhibitory activity

obtained from the microscale liver or GIA assays will be correlated to reactivity intensities to each antigen on 

the 1,087 Pf protein microarray and in combinations using a stage-specific combinatorial approach to calculate 

correlation coefficients and significance values with Benjamini-Hochberg adjustment for multiple testing. 

d) Statistical modeling to integrate functional data to multi-parameter data and immune outcomes: To integrate

the parasite-inhibitory activity scores with parameters measured in Aim 1 and immune outcomes, we will 

 

 

 

 

 

 

 

 

 

 

Research Strategy Page 97
Contact PD/PI: Tran, Tuan Manh

include inhibitory activity scores as two additional parameters (one each for microscale liver and for GIA) in the 

models for which the multinomial outcome is clinically immune (Class A+B), sterilely immune (Class E) or fully 

susceptible (Class C+D). We will use modeling and validation approaches described in Aim 1 to gain unbiased 

insight into the biology of parasite-inhibitory activity. Models will use parameters measured in Aim 1, including 

gender and age, as predictors and parasite-inhibitory activity scores as the outcomes. We will formally 

compare the accuracy of machine learning algorithms and regression models in selecting variables predictive 

of parasite inhibitory activity. We will also include functional scores as co-variates in Cox regression models to 

determine the effect of in vitro parasite-inhibitory activity on time-to-first Pf infection or malaria episode. 

3.3.3. Expected outcomes – Aim 2 

 Direct comparisons of high-dimensional biological datasets between clinically and sterilely immune groups 

are expected to provide novel insights into naturally acquired immunity. We hypothesize that the sterilely 

immune signature will be driven by IFN responses and a balanced antibody profile targeting both preerythrocytic and blood-stage antigens, whereas the clinically immune signature will be biased towards 

and have a predominantly blood-stage specific antibody profile. Our functional studies will formally test whether 

plasma from immune children will inhibit hepatocyte invasion, intrahepatocyte development, or erythrocyte 

invasion. We observed variability in the IgG responses against liver- and blood-stage antigens among 

protected children (Fig. 2B) as well as variability in hepatocyte-invasion activity of plasma from a separate 

group of Malian individuals in a pilot study (Fig. 3). Thus, in the current proposal, we also expect marked 

variation in the ability to inhibit Pf invasion of host cells, with certain samples conferring inhibition of invasion 

preferentially to hepatocytes or to erythrocytes. We hypothesize that plasma from sterilely immune children will 

inhibit parasite invasion of both hepatocytes and erythrocytes in vitro. We expect that parasite-inhibitory activity 

will correlate with increased IgG reactivity intensity against both pre-erythrocytic and merozoite antigens and 

independently associate with reduced risk of Pf infection in Cox regression models. This approach would allow 

us link functional responses to distinct antigen-specific IgG reactivity profiles and clinical outcomes. 

3.3.4. Anticipated Problems and Limitations – Aim 2 

Direct comparison of clinical and sterile immunity in the single platform comparison will be considered 

exploratory due to small sample sizes. However, pathways analysis might increase explanatory power in the 

case that we encounter only modest differences in gene expression between groups (67). Variability in the 

inhibitory activity of plasma samples in the functional assays could decrease our ability to detect group 

differences but may enhance our ability to correlate parasite-inhibitory activity to other parameters such as 

antigen-specific IgG or cell immuno-phenotypes. Nevertheless, identification of just a few individuals with an 

enhanced ability to inhibit hepatocyte or erythrocyte invasion will provide a basis for further studies into the 

mechanism of sterile protection, especially since these individuals remain enrolled in this cohort study. 

4. Rigor of Experimental Design and Quality Control 

 For all experiments, sample processing will be randomized to ensure equal distribution of classes, gender, 

and age among batches as to minimize batch effects. Time points from the same child will be processed 

together, allowing each child to serve as his/her own healthy baseline control. Sample processing procedures 

will be thoroughly documented. The raw data and final scripts for the processing and analysis of the data will 

be made publicly available at the conclusion of the project to allow others to reproduce our analysis. 

5. Research and Publication Timeline/Future Directions 

Methodical analysis of high-throughput data generated from 

samples that are linked to a well-characterized observational 

malaria cohort study will allow us to determine predictors and 

elucidate mechanisms of immunity to Pf infection. Studies 

proposed in this application will provide the PI with valuable 

experience in generating, modeling, validating, and interpreting 

complex data and further his development as a systems biologist 

of human immune perturbations. The practical implications of 

this work include identifying novel molecular or cellular predictors 

of natural immunity to Pf within the vaccine target population that 

could provide rational benchmarks for candidate malaria vaccines in clinical trials. Results from these studies 

will help elucidate the molecular patterns and mechanisms underlying the natural immune response to Pf 

infection and generate hypotheses for further mechanistic studies of malaria immunity. Through successful 

completion of this proposal, the PI will gain technical expertise in mathematical modeling and additional 

experience analyzing large datasets while generating the results necessary for manuscripts that will form the 

basis for subsequent independent, R01-level funding in the fields of malaria immunity and systems biology. 

Timeline (program year) 1 2 3 4 5

Aim 1

Laboratory/data generation

Computational analysis

Presentations/Manuscripts

Aim 2

Laboratory/data generation

Computational analysis

Presentations/manuscripts

R01 grant preparation

Research Strategy Page 98
Training in the Responsible Conduct of Research

I arrived at IUPUI in September 2015 and completed the Collaborative Institutional Training Initiative (CITI) 

Miami on-line courses on Good Clinical Practice, Responsible Conduct of Research and Human Subjects 

Research for Biomedical Researchers with inclusion of the International Research, Research with Children, 

and Genetic Research in Human Populations supplemental modules to provide me with formal training in these 

areas. I will maintain CITI certification at least every three years with refresher courses.

I will also enroll in the Introduction to Research Ethics course (GRAD G504) through the Indiana Clinical 

and Translational Sciences Institute to participate in face-to-face, small group discussions (meetings are for 1.5 

hours, 15 times during a semester, 22.5 contact hours) on these ethical issues in research: 

1. Science, Industry and Conflicts of Interest

2. Scientific Misconduct: Current Definitions, Policies, and Procedures

3. Responsible Authorship and Publications 

4. Policies Regarding Human Subjects, Animal Subjects in Research, and Safe Laboratory Practices

5. International Research Ethics

6. Peer Review Practices

7. Scientists as Responsible Members of Society

IUSM’s Center for Bioethics offers two venues for further in-depth group discussion in responsible conduct 

in research. I will participate in the Teaching Skills in International Research Ethics Workshop, which is an 

annual workshop aimed at building research ethics capacity between Indiana University and Moi University in 

Eldoret, Kenya, and the Global Bioethics Seminar Series offered every spring. These two workshops will 

address:

1. Mentor/mentee responsibilities and relationships

2. Collaborative research

3. Data acquisition, management, sharing, and ownership

My primary mentor Dr. John and my Division Director Dr. Wools-Kaloustian will ensure that I maintain 

current knowledge in the responsible conduct of research and that all my activities abroad have appropriate 

Institutional Review Board approval both in the United States and the site of my future collaborative malaria 

field research in Kenya. In addition, both Dr. John and Dr. Wools-Kaloustian will be available to discuss 

specific ethical issues that I may encounter while I develop my clinical research protocols for the collection of 

human biospecimens, which will be submitted for approval by the IUPUI and Kenyan IRB prior to future 

research proposals (anticipated to be in Years 4 and 5 of the current Research Plan). 

Contact PD/PI: Tran, Tuan Manh

Training in the Responsible Conduct of Research Page 99
Contact PD/PI: Tran, Tuan Manh
Contact PD/PI: Tran, Tuan Manh
Contact PD/PI: Tran, Tuan Manh
Contact PD/PI: Tran, Tuan Manh
Contact PD/PI: Tran, Tuan Manh
Contact PD/PI: Tran, Tuan Manh
Contact PD/PI: Tran, Tuan Manh
Contact PD/PI: Tran, Tuan Manh
Contact PD/PI: Tran, Tuan Manh
Contact PD/PI: Tran, Tuan Manh
Contact PD/PI: Tran, Tuan Manh
Contact PD/PI: Tran, Tuan Manh
Contact PD/PI: Tran, Tuan Manh
Contact PD/PI: Tran, Tuan Manh
Contact PD/PI: Tran, Tuan Manh

Inclusion of Women and Minorities Page 114
PHS Inclusion Enrollment Report

This report format should NOT be used for collecting data from study participants.

OMB Number:0925-0001 and 0925-0002

Expiration Date: 10/31/2018

 

Tracking Number: GRANT12212200 Funding Opportunity Number: PA-16-191. Received Date: 2016-07-12T10:54:42.000-04:00

*Study Title: Defining clinical and sterile immunity to Plasmodium falciparum infection using systems biology approaches

*Delayed Onset Study? ❏ Yes ❏✔ No

If study is not delayed onset, the following selections are required:

Enrollment Type ❏ Planned ❏✔ Cumulative (Actual)

Using an Existing Dataset

or Resource

❏✔ Yes ❏ No

Enrollment Location ❏ Domestic ❏✔ Foreign

Clinical Trial ❏ Yes ❏✔ No

NIH-Defined Phase III

Clinical Trial

❏ Yes ❏✔ No

Comments:

The proposal qualifies as Exempt Human Subject Research. The current proposal will only utilize existing, "in-the-freezer" human biological specimens

and existing clinical data from an ongoing cohort study on naturally acquired malaria immunity in Kalifabougou, (Mali ClinicalTrials.gov Identifier

NCT01322581). Both human speciments and clinical data have been coded so that the investigator cannot identify the subjects directly or through

identifiers linked to the subjects.

Racial Categories

Ethnic Categories

Not Hispanic or Latino

Female Male Unknown/

Not Reported

Hispanic or Latino

Female Male Unknown/

Not Reported

Unknown/Not

Reported Ethnicity

Female Male Unknown/

Not Reported

Total

American Indian/Alaska Native 0 0 0 0 0 0 0 0 0 0

Asian 0 0 0 0 0 0 0 0 0 0

Native Hawaiian or

Other Pacific Islander 0 0 0 0 0 0 0 0 0 0

Black or African American 344 351 0 0 0 0 0 0 0 695

White 0 0 0 0 0 0 0 0 0 0

More than One Race 0 0 0 0 0 0 0 0 0 0

Unknown or Not Reported 0 0 0 0 0 0 0 0 0 0

Total 344 351 0 0 0 0 0 0 0 695

Report 1 of 1

Contact PD/PI: Tran, Tuan Manh

 Page 115
Inclusion of Children

The current proposal will use biospecimens and clinical data from ongoing clinical studies on naturally acquired 

malaria immunity in Kalifabougou, Mali (ClinicalTrials.gov Identifier NCT01322581). Enrollment for this study

was based on a randomized, age-stratified census. This proposal specifically will utilize blood samples 

obtained from children aged 6 months-12 years. This age range captures the period during which immunity 

to P. falciparum infection is acquired in areas of intense malaria transmission like Mali and, thus, the target 

population for a malaria vaccine. Age will be included as a covariate in statistical models.

Assent forms were used for all study subjects between 7 and 18 years of age who are capable of giving their 

assent to participate. Parental consent was obtained for all study subjects since they were under 18 years of 

age. For minor’s parents who were both under 18 years of age, consent was obtained from a grandparent, in 

accordance with Malian custom. 

All experiments outlined in this proposal will use existing, cryopreserved biospecimens. 

No additional children will be recruited for this proposal.

There is no additional risk to the subjects, since this proposal makes use of biospecimens that have 

been previously collected and stored. 

Contact PD/PI: Tran, Tuan Manh

Inclusion of Children Page 116
Data and resource sharing plan

Materials generated under the project will be disseminated in accordance with Indiana University 

School of Medicine and NIH policies. Depending on such policies, materials may be transferred to others under 

the terms of a material transfer agreement. Raw sequence data files will be submitted to the NCBI Sequence 

Read Archive (SRA), and processed sequence data files will be submitted to the NCBI Gene Expression 

Omnibus (GEO). Processed data files containing Plasmodium falciparum sequences will be submitted to 

EuPathDB (PlasmoDB). Transcriptomic and antibody profiling data will be presented at scientific meetings. 

Custom scripts for processing and analyzing high-throughput data sets will be made publicly available at the 

conclusion of the project either prior to or at the time of publication. Presentations from the proposed projects 

will be presented at the following national and international meetings: Annual Meeting of the American Society 

of Tropical Medicine and Hygiene, Infectious Diseases Society of America Annual Meeting, and the Gordon 

Research Conference on Malaria. Publication of data shall occur during the project, if appropriate, or at the end 

of the project, consistent with normal scientific practices. 

Contact PD/PI: Tran, Tuan Manh

Resource Sharing Page 117
Authentication of Key Biological and/or Chemical Resources

Growth Inhibition Assays

Type O+ human erythrocytes used in the growth inhibition assays (GIAs) will be obtained from the Indiana 

Blood Center. Plasmodium falciparum 3D7 blood stage parasites used in GIAs will be cultured from 

cryopreserved stocks (courtesy of Jianbing Mu, National Institute of Allergy and Infectious Diseases) that have 

been authenticated as 3D7 by 6-loci microsatellite genotyping.

Hepatocyte Invasion Assays

For the microscale human liver platform (also called micropatterned co-culture assay), Dr. Sangeeta Bhatia’s 

laboratory uses commercially available cryopreserved primary human hepatocytes (BioreclamationIVT; 

Invitrogen) and 3T3-J2 murine embryonic fibroblasts (courtesy of Howard Green, Harvard Medical School). 

Sanaria (Rockville, Maryland) will supply the P. falciparum NF54 for this study.

Flow cytometry

Antibodies used for flow cytometry will be purchased from three commercial vendors: BioLegend, BD 

Biosciences and R&D systems. The following are anticipated antibodies based on our prior experience:

Panel Marker Fluorochrome Clone Catalog

Surface CD19 Brilliant Violet 785 HIB19 302240

Surface CD21 APC HB5 17-0219-42

Surface CD27 Brilliant Violet 421 M-T271 356418

Surface CD10 Brilliant Violet 510 HI10a 312219

Surface CD23 PE-Cy7 B3B4 101613

Surface IgG PE-CF594 G18-145 562538

Surface CD95 Brilliant Violet 605 DX2 305627

Surface CD14 Brillian Violet 785 M5E2 301840

Surface CD16 Brilliant Violet 605 3G8 302040

Surface anti-FcεRI, common γ subunit FITC 2472959 FCABS400F

Surface CD3 Horizon V500 UCHT1 561416

Surface CD4 PerCP RPA-T4 300527

Surface CD8 Brilliant Violet 570 RPA-T8 301038

Surface CD56 Brilliant Violet 711 HCD56 318335

Surface TCR γ/δ APC B1 331211

Surface FCRL5 PE 509f6 340304

Intracellular Phospho-STAT6 (Y641) PE IC3717P

Intracellular T-bet PE-CF594 O4-46 562467

Intracellular STAT6 APC 253906 IC2167A

Intracellular GATA3 PE-Cy7 L50-823 560405

Intracellular IFN-γ APC/Cy7 4S.B3 502529

Intracellular IL-6 PE MQ2-13A5 501106

Contact PD/PI: Tran, Tuan Manh

Authentication of Key Biological and/or Chemical Resources Page 118